DIPLOMARBEIT

Titel der Diplomarbeit
„SCN9A and its natural antisense transcript“

Jennifer König

angestrebter akademischer Grad
Magistra der Naturwissenschaften (Mag.rer.nat.)

Wien, Oktober 2011

Studienkennzahl lt. Studienblatt: A 490
Studienrichtung lt. Studienblatt: Molekulare Biologie
Betreuerin / Betreuer: Univ.Prof Dr.Juergen Sandkuehler
Table of Content

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>i</td>
<td>Abstract English</td>
</tr>
<tr>
<td>ii</td>
<td>Abstract German</td>
</tr>
<tr>
<td>1.1</td>
<td>Pain perception - nociception</td>
</tr>
<tr>
<td>1.2</td>
<td>Primary afferents and transduction</td>
</tr>
<tr>
<td>2.0</td>
<td>Transmission</td>
</tr>
<tr>
<td>2.1</td>
<td>Voltage gated sodium channels - introduction</td>
</tr>
<tr>
<td>2.2</td>
<td>Nav1.7 – A hot spot for human pain disorders</td>
</tr>
<tr>
<td>2.2.1</td>
<td>SCN9A protein structure</td>
</tr>
<tr>
<td>2.2.2</td>
<td>Nav1.7 electrophysiological properties</td>
</tr>
<tr>
<td>2.2.3</td>
<td>Nav1.7 and inflammation</td>
</tr>
<tr>
<td>2.2.4</td>
<td>Nav1.7 mutations and inherited human pain syndromes</td>
</tr>
<tr>
<td>2.2.4.1</td>
<td>Primary erythermalgia (PE)</td>
</tr>
<tr>
<td>2.2.4.2</td>
<td>Paroxysmal extreme pain disorder (PEPD)</td>
</tr>
<tr>
<td>2.2.4.3</td>
<td>Channelopathy-associated insensitivity to pain (CIP)</td>
</tr>
<tr>
<td>2.2.5</td>
<td>Other voltage gated sodium channels and associated pain syndromes</td>
</tr>
<tr>
<td>2.2.5.1</td>
<td>Nav1.3 and neuropathic pain</td>
</tr>
<tr>
<td>2.2.5.2</td>
<td>Nav1.8 inflammation and neuropathic pain</td>
</tr>
<tr>
<td>2.2.5.3</td>
<td>Nav1.9</td>
</tr>
<tr>
<td>2.3</td>
<td>Future prospective – a new desirable class of drugs</td>
</tr>
<tr>
<td>3</td>
<td>Natural antisense transcript</td>
</tr>
<tr>
<td>3.1</td>
<td>Classification of NATs</td>
</tr>
<tr>
<td>3.2</td>
<td>NAT detection strategies and pitfalls</td>
</tr>
<tr>
<td>3.3</td>
<td>Antisense transcription</td>
</tr>
<tr>
<td>3.4</td>
<td>Functional and biological role of natural antisense transcripts</td>
</tr>
<tr>
<td>3.4.1</td>
<td>mRNA–antisense RNA interaction: RNA editing, RNAi and RNAmasking</td>
</tr>
<tr>
<td>3.4.1.1</td>
<td>RNA editing</td>
</tr>
<tr>
<td>3.4.1.2</td>
<td>RNAi</td>
</tr>
<tr>
<td>3.4.1.3</td>
<td>RNA masking</td>
</tr>
<tr>
<td>3.4.2</td>
<td>DNA–antisense RNA interactions: transcriptional interference, chromatin remodelling and epigenetics</td>
</tr>
</tbody>
</table>
3.4.2.1 Transcriptional interference

3.4.2.2 Chromatin remodelling and epigenetics

4 SCN9A and its corresponding antisense transcript

5 Materials and Methods

5.1 Gels, LB and Plates

5.1.1 Agarosis gel

5.1.2 1kb Ladder

5.1.3 100bp Ladder Invitrogen

5.1.4 LB

5.1.5 LB Agar

5.1.6 Antibiotics

5.2 RNA isolation

5.3 Cloning, Kits and PCR

5.3.1 OneShot© Top10 chemically competent cells

5.3.2 XL10-Gold ultracompetent Cells

5.3.3 Miniprep

5.3.4 Maxiprep

5.3.5 Gel purification

5.3.6 PCR Purification

5.3.7 DreamTag Green DNA polymerase kit

5.4 Restriction digests

5.5 SuperScript Reverse Transcriptase

5.6 Phusion high fidelity DNA polymerase

5.7 Ear DNA Extraction for PCR – Isolation of Genomic DNA

5.8 Mouse Total RNA Master Panel

5.9 Vectors

5.9.1 A Cloning of human full length antisense transcript

5.9.1B Cloning of mouse full length antisense transcript

5.9.2 Expression vector

5.9.2.2 SAP Treatment of pcDNA3

5.9.2.3 Ligation of full length Nav1.7 antisense transcript to pcDNA3 vector

5.9.2.4 Transformation of human/mouse antisense into chemically competent
E.coli cells

5.9.2.5 Sequencing – Bioinformatics

5.9.3 Additional vector: pEGFP vector and human SCN9A – IRES – DsRED2

5.10 Primer

5.10.1 Primer mouse AK138532 antisense: full list

5.10.1.1 Full length SCN9A antisense transcript

5.10.1.2 SCN9A sense – sequencing

5.10.1.3 Additional sequencing Primer

5.10.1.4 Mouse tissue panel

5.10.2 Primer human Nav1.7 sense and antisense transcript

5.10.2.1 Primer Human BC051759 antisense transcript: full list

5.10.2.2 Full length SCN9A antisense transcript

5.10.2.3 Sequencing primer

5.11 Cell culture

5.11.1 Cell lines

5.11.2 Cell culture media - MG

5.11.3 Cell splitting

5.11.4 Coating

5.11.5 Transfection

5.11.5.1 Transfection of Nav1.7 stable expressing cell line for immunohistochemistry

5.11.5.1.1 Immunohistochemistry

5.11.5.2 Transfection of Nav1.7 and Nav1.6 stable cell line for patch clamp

6. Results SCN9A and its corresponding antisense transcript

6.1 Bioinformatics

6.2 Mouse tissue panel

6.3 Immunohistochemistry

6.4 Electrophysiology

7. Discussion

References

Weblinks and Databases

Supplemental Data and Appendix

CV Jennifer König
i. Abstract English

Pain is an essential part of our survival and keeps us in awareness of our physical limitations and protects us from harmful environmental stimuli. However, pain and other somatosensory submodalities like vision and smell are rather a perception, a product of our brain to handle and bring external sensory inputs to consciousness (10, 18). Regardless of its essential role in one’s survival, pain and in particular chronic pain which does not fulfil any physiological role, is a major clinical challenge to treat (15, 16). Currently 10% of the population are suffering from chronic pain due to irreversible nerve injury or inflammation. Up to now the two major classes of analgesics that are used to treat chronic pain (i.e. non-steroidal anti-inflammatories and the opioids) focus more on the symptoms of pain than its underlying causes. Recent scientific discoveries obtained from mice in knockout (31,32), knock down and overexpression studies as well as analyses of patients suffering from unusual pain states (20) show that voltage gated sodium channels are key players in several pain pathways.

In particular Nav1.7, a TTX sensitive voltage gated sodium channel that is mainly expressed in sensory DRG neurons and sympathetic ganglia neurons, is fundamental in initiation and propagation of action potentials (9-21, 23) and plays an important role in pain sensation. Inherited or spontaneous mutations in SCN9A (Nav1.7) causing a gain of function result in hyperexcitability of DRG neurons and lead to Primary erythermalgia (PE) (12,14,21) and Paroxysmal extreme pain disorder (PEPD) while nonsense mutations causing loss of function of Nav1.7 cause Channelopathy-associated insensitivity to pain (20, 17).

Interestingly, SCN9A has a corresponding antisense transcript encoded on the opposite strand that tail to tail overlaps with the sense transcript and might play a role in regulation of SCN9A expression. Different studies have reported independently that natural antisense transcripts have an impact on the transcription level of its corresponding sense gene either through 1) interfering with its transcription 2) RNAi, RNA editing and RNA masking 3) or through epigenetic and chromatin remodelling (1).

By investigating the possible mechanism of SCN9A antisense transcripts on Nav1.7 expression, we aim to gain deeper insights into pain pathways and contribute to the development of a new specific class of analgesic drugs.
ii. Abstract German


Interessanterweise hat SCN9A ein correspondierendes Antisense-Transkript auf dem gegenüberliegenden Strang, das tail to tail angeordent ist und möglicherweise eine Rolle in der Regulation der Expression SCN9A spielt. Verschiedene Studien haben unabhängig
voneinander gezeigt, dass Antisense-Transkripte Auswirkungen auf die Expression des sense Transkription des entsprechenden Gens haben, entweder durch 1) störung seine Transkription 2) RNAi, RNA-Editing-und RNA-Maskierung 3) oder durch Epigenetics und Chromatin-Remodeling. (1)

1. Introduction

1.1 Pain perception – Nociception

Pain is like other sensory sub-modalities a perception but in comparison to colour perception, pain does not only have a perceptual component but also highly psychological and cognitive components (10). In other words, our internal pain scale or how we rate pain can change due to severe injury and might influence how we experience pain in the future (60). By contrast, pain research in the last couple of years suggests that our internal pain scale is based on our genetic background. In particular, research in the field of nociception and voltage gated sodium channels has brought evidence that even single nucleotide polymorphisms (SNP) or spontaneous point mutations in these channels can have a significant influence on pain thresholds and our internal pain scale (20).

A more generalized definition of what pain is comes from the International Association for the Study of Pain (IASP) defining pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage” (http://www.iasp-pain.org). What is undisputable is that pain is a crucial, non-redundant part of our survival, showing us our limits and protecting us from greater harm. This becomes even clearer in patients affected by congenital inability to experience pain (20), not feeling any pain at all leads to severe injuries and consequently can reduce one’s life expectancy dramatically. Although pain is fundamental, chronic inflammatory pain instead does not fulfil any protective purpose and strongly decreases a patient’s quality of life. (15)

1.2 DRG neurons: primary afferents and transduction

Nociceptor. Pain sensation is mediated by a special subset of sensory neurons, called nociceptors that innervate the tissue with its bare nerve endings. Nociceptors are activated through environmental stimuli such as heat, cold, and chemicals. Activation leads to structural changes with corresponding opening and closing of ion channels and subsequent alteration of physiological and electrical properties of these channels. The main classes of
nociceptors can be distinguished by their afferent fibres, activating stimuli and distribution in skin and deep tissue (18). The two main classes of afferent fibres are slowly conducting unmyelinated C fibres and fast conducting thinly myelinated Aδ fibres (10). Conduction velocity differs between these two fibre types and they are also associated with different types of pain sensation.

First and second pain. In comparison to other somatosensory receptors like mechanoreceptors that terminate in specialized structures, nociceptors that mediate pain sensation end in bare nerve endings (10). Fast conduction Aδ fibres have a conduction velocity of 5-30 m/s and are involved in first pain sensation, a rapidly perceived pain that carries information about what and where an incident happened. By contrast 2nd pain is much less informative and discriminative than 1st pain. It is mediated by slowly conducting unmyelinated C fibres with a conduction velocity of 1 m/s (18).

DRG neurons, most of which are nociceptors are pseudo unipolar neurons with their axons dividing into classic T junctions with peripheral and central branches. The peripheral branch consists of free nerve endings, mainly unmyelinated C fibres that innervate the tissue while the central branch projects its axon to 2nd order neurons in the spinal cord (10). Cell bodies of nociceptors are found in the dorsal root ganglia and vary in size, sets of channels expressed and gene expression. Among a variety of other channels, ion channels like the TRP (transient receptor potential) family are found on the axon tip of afferent fibres and respond to noxious stimuli such as acid, heat, cold and eicosanoids (15).
In the presence of a noxious stimulus these ion channels open and create a receptor potential that leads to a depolarization of the membrane. Additionally voltage gated sodium channels like Nav1.7, Nav1.1, Nav1.6 and Nav1.8 are also found near the peripheral terminals of nociceptors and activate when a certain threshold is reached. Mainly the activation of Nav1.7 voltage gated sodium channels contributes to initiation and propagation of action potentials (28).

2. Transmission
2.1 Voltage gated sodium channels – Introduction
Sodium channels are integral membrane proteins containing 4 homologous domains each of which consists of 6 transmembrane segments (S1 to S6) (20, 11) that form voltage sensitive and ion selective pores (21). These alpha subunits are connected to each other via intracellular and extracellular loops (11, 28). The sodium channel’s voltage sensor is found in the S4 alpha helix in each of the four alpha subunit domains (I-IV) (11, 20). Voltage sensor residues in S4 are either lysine or arginine that are arranged in an interval of every 3rd amino acid, allow only positively charged Na+ ions and only at an appropriate membrane potential to enter through the pore by opening or otherwise closing the channel pore (21).

The molecular weight of the alpha subunits is around 220-260 kDa and each voltage gated sodium channel is associated with auxiliary beta subunits. Four different beta subunits (β1, β2, β3, β4) have been identified (19, 21, 25). Beta subunits are single transmembrane proteins with an intracellular and extracellular binding domain. Interestingly the extracellular domain of β- subunits is homologous to a V-set (Ig-related domains of non-Ig molecules are described as being V-like when they are have a pattern of β-strands: V and V-related domains have about 65-75 amino acid residues between the conserved disulphide bond, and there are four β-strands in each β-sheet plus a short β-strand segment across the top of the domain, (22)) of Ig superfamily like adhesion molecules. Still not completely understood is what function β subunits fulfil to modulate VGSCs. It is hypothesized that β subunits interact with the cytoskeletal and the extracellular matrix (21) via their V set Ig domain and thereby might play a role in stabilizing the Nav proteins in the membrane (19) or help to even guide Nav polypeptides to membrane sites (19,21,25). Moreover, studies using Xenopus laevis oocytes with human β subunits indicate that they even modulate the gating properties of the alpha subunit (13). Co-expression of certain α subunits with a specific auxiliary β- subunit has been shown to modulate sodium channel properties (13, 19) by changing activation / inactivation properties of VGSCs. For example, Nav1.2 co-expressed with β1A subunit leads to a 2.5 fold increase in sodium current density due to increased channel functionality (21, 25).

All nine pore-forming isoforms (Nav1.1 – Nav1.9) of the alpha subunits are encoded by different genes (9-21, 13, 14) (see Table A). In particular Nav1.1, Nav1.2, Nav1.3 and Nav.1.7 are closely structurally and functionally related and are encoded by a set of four genes clustered in the chromosomal locus chr.2q24.3. Each of the nine sodium channel
isoforms has its own highly specific distribution pattern within the CNS and peripheral nervous system (14) (Table A). Nav1.7 is highly expressed in sensory DRG neurons and sympathetic ganglion neurons, Nav1.8 and Nav1.9 are primarily found in damage sensing DRG neurons and nerve fibres (16, 25).

In humans, voltage gated sodium channels are highly conserved and show 75% primary sequence homology of the transmembrane and extracellular domains (25). Voltage gated sodium channels can be distinguished by their ability to respond to TTX, a tetrodotoxin from puffer fish which binds to the ion selective pore (12). Nav1.1 to 1.4 as well as 1.6 and Nav1.7 are TTX sensitive and respond to nanomolar concentrations of TTX while Nav1.5, Nav1.8 and Nav1.9 are even insensitive to micromolar concentrations of TTX (21).

**Mechanism of Action**

Voltage gated sodium channels mainly contribute to action potential generation and propagation. Through their voltage sensor and ion-selective pores they allow the rapid influx of Na+ ions during the upstroke of an action potential (9, 13, 14, 15, 16).

Structural conformation of voltage gated sodium channels changes with changing membrane potential and can either be (a) open (active state), induced via membrane depolarization; (b) fast inactivated, which occurs when the cytoplasmic loop binds to the pore of the VGSC to terminate the sodium flow and leads to (c) closed state: repriming (recovery from inactivation), which occurs while the membrane potential is repolarizing to get back to the resting membrane potential at -80mV (13). This simplistic view of Nav1 open and closed states has been proven to not hold entirely true for all voltage gated sodium channels. In particular VGSC found in DRG neurons, where a heterologous set of different sodium channels is present, show a more complex pattern of expressing currents. Patch clamp experiments with VGSCs identified sodium channels to be either sensitive or resistant to TTX. TTX sensitive VGSCs are rapidly inactivating while TTX resistant sodium channels slowly inactivate and might serve to prolong the action potential duration due to the longer open state of the channels leading to increased neurotransmitter release at the nerve terminals (13, 14).

**2.2 Nav1.7 a hot spot for human pain disorders**
SCN9A encodes for the alpha subunit of the TTX sensitive voltage gated sodium channel Nav1.7 (9, 16, 20) which is mainly found in slowly conducting (13) small diameter DRG neurons and sympathetic ganglion neurons. Nav1.7 is also very weakly expressed in the CNS (31). Immunohistochemistry with a specific antibody against Nav1.7 located the sodium channel at distal ends of neuritis. Human Nav1.7, (gene symbol SCN9A) is encoded on chromosome 2q24.3 and is a 113 kb gene that is comprised of 26 exons which are translated into a 1977 amino acid long polypeptide. Nav1.7 is crucial in initiation and propagation of action potentials (9-21, 23). Interestingly Nav1.7 is also found in olfactory sensory neurons and seems to connect the two sensory modalities, smell and pain. Patients suffering from Channelopathy-associated insensitivity to pain and anosmia have loss of function mutations in Nav1.7, causing the compromised function of nociceptors and olfactory neurons. (27)

2.2.1 SCN9A protein structure - See Fig2. and supplemental data 1

- SCN9A primary amino acid sequence is 1977 amino acids long.
- Ion selective pore: a re-entrant loop between helices S5 and S6 is embedded into the transmembrane region of the channel to form a narrow, ion selective filter at the extracellular end of the pore (35).

<table>
<thead>
<tr>
<th>Ion Trans</th>
<th>AS Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trans I</td>
<td>AS 356 - 365</td>
</tr>
<tr>
<td>Trans II</td>
<td>AS 911 - 920</td>
</tr>
<tr>
<td>Trans III</td>
<td>AS 1390 - 1399</td>
</tr>
<tr>
<td>Trans IV</td>
<td>AS 1682 - 1691</td>
</tr>
</tbody>
</table>

- Transmembrane regions
- Coiled coil region AS 402 - 449
- Sodium Ion transport associated domain AS 969 – 1191
- IQ AS 1877 – 1899
- Exon 5 has an alternative splicing variant (57)

YLTEFVNLGNVSALRTFRVLRALKTISVIP
YVTEFVDLGNVSALRTFRVLRALKTISVIP
• IFM Motif AS 1461 – 1463, IFM motif and the charged residues in the domain III-IV linker identified to be critical for the fast inactivation kinetics of the rat brain II channel (36)
• Tetrodotoxin sensitivity defining amino acid AS Y362, if this AS is mutated into a Serine it turns the channel into a TTX resistant one (37)

2.2.2 Nav1.7 electrophysiological properties

The Nav1.7 voltage gated sodium channel is highly sensitive to TTX and is predominantly found in C fibre axons of slowly conducting nociceptive DRG neurons and sympathetic ganglion neurons. Nav1.7 rapidly activates and inactivates from the open state within less than a millisecond (28) but, unlike other TTX sensitive VGSCs (12) it slowly recovers from fast inactivation (closed state inactivation) (12, 13). By slowly transiting to the closed inactivated state, Nav1.7 remains available for activation even with small or through slowly depolarizing potentials and serves as a threshold channel for Nav1.8 activation by amplifying incoming smaller current. In contrast Nav.1.8 voltage gated sodium channels only open at depolarization thresholds higher than Nav1.7 and is responsible for most of the inward current in the upstroke of action potentials (14).

2.2.3 Nav1.7 and inflammation

Nav1.7 is associated with inflammatory pain that occurs in response to prior tissue damage. Inflammation of the injured tissue leads to hypersensitivity in and around the affected area. Inflammatory mediators such as 5HT, prostaglandin and adenosine are released during acute tissue damage, (10) enhancing the magnitude of the voltage dependent Nav1.7 sodium current and shifting the Nav1.7 activating threshold to more hyperpolarized potentials. This increases the rates of activation and inactivation dramatically and in a second instance leads to increased sensitization of the nociceptors and the inflamed tissue (14). Hypersensitivity by increased excitability of a specific set of nociceptive neurons promotes healing and repair (12). Furthermore, CFA induced inflammation in mice leads to an up-regulation of Nav1.7 expression and increased amount of SCN9A transcripts (30).
Nociceptor-specific Nav1.7 k.o (31) and double k.o of Nav1.7 and Nav1.8 (32) confirmed Nav1.7’s important role in the development of inflammatory pain. Interestingly, both the Nav1.7 k.o. and the double k.o. are still able to develop neuropathic pain. However, global k.o of Nav1.7 in mice is lethal which is likely to be related to the importance of Nav1.7 to the sense of smell (29).

2.2.4 Nav1.7 mutations and inherited human pain syndromes

Nociceptive pain primarily functions in detection and protection against potential or acute noxious stimuli such as heat, chemical injury, nerve damage and myocardial ischemia that causes severe damage, and induces a pain sensation that is highly unpleasant and not neglectable. Normally, nociceptive pain persists as long as the external or internal noxious stimulus is present. Nav1.7 is linked to three inherited monogenic pain disorders (12). Gain of function mutations can result in Primary erythermalgia or Paroxysmal extreme pain disorder which are characterised by intensely painful episodes (13) whereas homozygous loss of function mutations can result in a congenital inability to experience any pain at all (20).

2.2.4.1 Primary erythermalgia (PE)

Inherited autosomal dominant Primary erythermalgia is caused by missense gain of function mutations in SCN9A that lead to an increased activity of Nav1.7 due to altered electrophysiological properties. Mutations are found in the transmembrane domains and intracellular linker domains (9) some of which are in highly conserved parts of the channel (e.g. L858H) (14) (Fig 1 overview, PE mutation). All 14 reported PE mutations cause lowering of the channel’s activation threshold. This leads to enhanced activity of Nav1.7 by shifting the voltage dependence of the channel to more hyperpolarized potentials. Moreover the majority of all reported PE mutations also affect the sodium channel’s transition to an inactivated state (from open to inactivate). Normally Nav1.7 is a fast activating and inactivating channel but certain mutations result it in staying open for longer, leading to a larger inward current. Other mutations like I136V, L858F, A863P and F1449V, additionally speed up the voltage gated channel’s repriming (recovery from inactivation).
Also a correlation between certain mutations and age of PE onset has been determined. Mutations such as I848T are linked to early onset of PE while others like Q10R are linked to late onset which only leads to a small shift in activation threshold toward more hyperpolarized membrane potentials.

**Clinical symptoms characteristic for PE:** First clinical symptoms in patients suffering from PE appear in the first decade of their life with reddened feet and hands due to moderate physical exercising, exposure to warmth and/or after long periods of standing (14). In the later course of PE, there are episodes of persistent burning pain and redness of lower extremities which can extend to the upper legs, feet, and often hands which is accompanied by elevated temperature of the affected areas (9, 14).

### 2.2.4.2 Paroxysmal extreme pain disorder (PEPD)

PEPD is an inherited autosomal dominant disease characterized by sudden onset and reoccurring episodes of burning pain in different body parts. PEPD is caused, similar to PE, by mutations in SCN9A that lead to a gain of function in Nav1.7 (*see fig1 overview PEPD mutations*). In comparison to PE, all mutations that are found in Nav1.7 evoking PEPD (14, 28), do not enhance the voltage gated sodium channels activation but instead they impair its voltage dependent steady state inactivation. Most, but not all of the reported mutations that cause paroxysmal extreme pain disorder, shift the steady state inactivation to a more depolarized potential. This leads to incomplete inactivation of Nav1.7 (15), and decreases the actual threshold for initiation of the action potential and increases the number and duration of evoked AP in DRG neurons leading to hyperexcitability of these neurons (34).

**Clinical symptoms of PEPD:** Patients with PEPD suffer from excruciating painful episodes that primarily affect the rectal, submandibular and ocular regions. (14). Patients with PEPD are strongly affected during their childhood with reoccurring and stronger painful episodes, (34) often accompanied with non-epileptic seizures and cardiac symptoms (14, 29, 34). Interestingly in most individuals, PEPD symptoms diminish with age although there are a number of cases where PEPD was carried into their adulthood (28).

4 characteristic stages are defined in PEPD (12, 14)
1. Stage, directly after birth, new-born has red flushes all over the back, legs, and soles of the feet.
2. Stage, rectal pain, childhood: burning pain that suddenly appears and lasts for at least 1h. The burning pain slowly moves down to the lower extremities followed by red flushes on the soles of the feet, skin, scrotum, left and right foot and buttocks.
3. Stage, Ocular pain pattern, childhood: sudden onset of acute burning pain that lasts for a couple of minutes, followed by sporadic redness of skin, in particular in the temporal region and eyelids.
4. Stage, paroxysmal pain

Painful episodes are induced by eating hot, cold or spicy food; and by sunlight and strong wind. It is remarkable that although Nav1.7 is widely expressed within the PNS, PE and PEPD both show a highly specific tissue distribution of symptoms (14). This strong variation among these two diseases gives rise to the idea that Nav1.7 is probably not the only, but definitely an important part in developing PE and PEPD.

2.2.4.3 Channelopathy-associated insensitivity to pain (CIP)

CIP is a very rare inherited autosomal recessive disorder caused by recessive loss of function mutations in SCN9A. First insights into this highly unusual pain state were obtained through analysis of three consanguineous families from Pakistan (20). Due to the frameshift or the nonsense amino acid changes in either exon 10 (S459X), 13 (I767X) and exon 15(W897X) (14), SCN9A mRNA does not encode for a functional protein in these families. *(For all reported mutation in SCN9A see Overview fig 1 CIP).* Most patients suffering from CIP are from consanguineous families and are homozygous for the same mutation in SCN9A (9) and are from birth insensitive to painful stimuli but still respond to light sensation of touch, warm, cold, proprioception and pressure (20). While nociception is completely lacking in these individuals, any other physical and mental deficiencies could not be found. Despite having quite severe injuries that mainly go unnoticed and suffering from anosmia (27), they have an otherwise normal development, intelligence and health (20, 29). What is still not completely understood is why global Nav1.7 k.o in mice is lethal but in humans loss of functions mutations causes channelopathy associated insensitivity to pain in
otherwise healthy individuals. One explanation is that new-born mice with loss of Nav1.7 function are not able to find their mother’s mammary gland and die due to malnutrition. Interestingly mouse Nav1.7 shows a higher expression in the CNS compared to human Nav1.7, in particular in the brain nuclei such as the paraventricular hypothalamic nucleus and the supraoptic nucleus (9). Furthermore, variability in inter-human pain sensation can be caused by polymorphisms in SCN9A (14).

Fig1 Overview of all reported mutations in SCN9A causing PE (IEM), PEPD and CIP

Mutations reported in patients suffering from PE are found in the intracellular loops as well as in the conserved parts of the transmembrane domains of Nav1.7. PEPD mutations are mainly found in the intracellular linker regions. PE, PEPD are inherited autosomal dominant disorders whereas CIP is caused by inherited autosomal recessive mutations in SCN9A. PE enhances the channel activation, PEPD impairs Nav1.7 channel inactivation both leading to increased channel activity which is linked to hyperexcitability of DRG neurons.

2.2.5 Other voltage gated sodium channels and associated pain syndromes

2.2.5.1 Nav1.3 and neuropathic pain
Nav1.3 is a TTX sensitive voltage gated sodium channel mainly expressed in the adult central nervous system and during embryonic development. Its expression levels are normally very low in the PNS. Expression of Nav1.3 and β3 subunit in sensory but not primary motor neurons is only up-regulated due to nerve injury. Nerve injury also alters the level of neurotrophic factors like NGF and GDNF and reactivates the transcription of the normally transcriptionally silenced Nav1.3 VGSC (30, 25).

It was postulated that Nav1.3 up regulation might render DRG neurons hyperexcitable during nerve injury. This hypothesis was explained by Nav1.3 channel biophysical properties, fast inactivation after activation and fast repriming, while slowly inactivating from the closed state. The slow transition into a closed state, similar to Nav1.7, enables Nav1.3 to remain available for activation by small depolarizing potentials (30, 25). However Nav1.3 global and DRG specific k.o. mice do not show any amelioration in pain behaviour after nerve injury and is therefore not responsible for the hyperexcitability of DRG neurons seen after nerve injury.

2.2.5.2 Nav1.8 inflammation and neuropathic pain

Nav1.8 is a TTX resistant voltage gated sodium channel which is mainly found in free nerve endings of DRG neurons and in trigeminal ganglia (25). Its location at free nerve endings enables Nav1.8 to strongly contribute to the level of neuronal excitability and modulate and influence pain signalling significantly (21).

Electrophysiological properties: Nav1.8 is a slowly inactivating (transition from open to closed state) and fast repriming TTXr channel thus activation and inactivation occurs at depolarized and voltage dependant potentials (25). Nav1.8 is the most significant VGSC in the depolarization phase of action potentials in DRG neurons.

Interestingly, inflammatory mediators like NGF influence the expression level of Nav1.8 and TTXR current levels while others like prostaglandin E2 and serotonin shift the channel activation to more negative potentials by phosphorylation of specific serine residues via intracellular 2nd messenger proteins PKA/C (21, 25, 30). This means that inflammation results in an increased activation and inactivation of the VGSC. Nav1.8 k.o mice confirmed
its contributory role in inflammatory pain and surprisingly also in cold evoked pain but no clear evidence for a role of Nav1.8 in neuropathic pain has been determined (43).

2.2.5.4 Nav1.9

Nav1.9 is similar to Nav1.8 as this channel is predominantly expressed in small diameter nociceptive DRG neurons (25, 30). In comparison to Nav1.8, Nav1.9 expresses a permanent TTX resistant current due to its activation and inactivation properties at hyperpolarized potentials, which are around the cell’s resting membrane potential (13). The TTX resistant current expressed by Nav1.9 is mostly similar to the Nav1.5 cardiac current (25). Nav1.9 mainly contributes to the setting of DRG excitability by modulating the resting potential but due to its slow activating channel properties it does not engage in the depolarization phase of action potentials, like Nav1.8 does. Nav1.9 k.o and knock down mice treated with CFA expressed a reduced sensitivity to heat and mechanical pain suggesting a role for Nav1.9 in neuronal inflammatory pain, although there were no reported changes in Nav1.9 current properties (54). By contrast Nav1.9 k.o. does not influence acute pain and neuropathic pain thresholds.

2.3 Future prospective – a new desirable class of drugs

Currently two major classes of analgesics are used to treat chronic inflammatory pain: a) Non-steroidal anti-inflammatory drugs (taking hold through acting on arachidonic acid metabolism) and b) Opioids (acting on G proteins). However, these drugs can often be accompanied by severe side effects such as gastrointestinal bleeding (NSAIDs) and respiratory depression (opioids). Furthermore, the opioid class of drugs have issues associated with addiction and tolerance (15). To understand how pain works and to design new classes of drug that specifically target the source of pain rather than just only treating its symptoms, it is crucial to understand how noxious stimuli are transduced, transmitted and processed within the PNS and CNS. Nav1.7 plays a key role in nociception and inherited pain disorders and mutations within this gene can have drastic impacts on pain sensation. Although Nav1.7 gain of function (PE and PEPD) and loss of function (CIP) mutations
cause a spectrum of human pain disorders and anosmia (27), this voltage gated sodium channel does not seem to be involved in any other major pathway apart from pain and the sense of smell, which makes it an attractive target for a new class of analgesic drugs.

Table A: Overview voltage gated sodium channels (VGSC)

<table>
<thead>
<tr>
<th>VGSC</th>
<th>Chrom.</th>
<th>Tissue</th>
<th>TTXs</th>
<th>Symptoms/Disease</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nav1.1</td>
<td>2q24.3</td>
<td>CNS/PNS</td>
<td>+</td>
<td>Epilepsy, Migraine</td>
<td>Dichgans et al 2005 (61)</td>
</tr>
<tr>
<td>Nav1.2</td>
<td>2q24.3</td>
<td>CNS</td>
<td>+</td>
<td>Ko:Brainstem Apoptosis followed by severe Hypoxia,</td>
<td>Planell-Cases, 2000 (24)</td>
</tr>
<tr>
<td>Nav1.3</td>
<td>2q24.3</td>
<td>Adult CNS, Low level in DRG, Embryonic DRG</td>
<td>+</td>
<td>Up regulated in mice with normal acute and inflammatory pain</td>
<td>Nassar et al 2006 (33)</td>
</tr>
<tr>
<td>Nav1.4</td>
<td>17q23.3</td>
<td>Skeletal muscle</td>
<td>+</td>
<td>Hyperkalemic periodic paralysis</td>
<td>Lerhman-Horn et al., 2002 (26)</td>
</tr>
<tr>
<td>Nav1.5</td>
<td>3p22.2</td>
<td>Heart/CNS</td>
<td>-</td>
<td>Visceral pain</td>
<td>Wilde et al 2011 (65)</td>
</tr>
<tr>
<td>Nav1.6</td>
<td>12q13.13</td>
<td>CNS</td>
<td>+</td>
<td>Impaired motor function</td>
<td>Levin et al 2006 (66)</td>
</tr>
<tr>
<td>Nav1.7</td>
<td>2q24.3</td>
<td>DRG and sympathetic neurons</td>
<td>+</td>
<td>PEPD, PE, CIP, chronic inflammatory pain, Congenital pain disorder</td>
<td>Nassar et al 2004 (31), Fertelman et al 2006 (62), Cox et al 2008 (20)</td>
</tr>
<tr>
<td>Nav1.8</td>
<td>3p22.2</td>
<td>DRG</td>
<td></td>
<td>Cold pain, inflammation SNP in heart expressed Nav1.8 increases the risk of aterial fibrillation and heart attacks</td>
<td>Nassar et al 2005, Akopian et al (64)</td>
</tr>
<tr>
<td>Nav1.9</td>
<td>3p22.2</td>
<td>DRG</td>
<td></td>
<td>Inflammation</td>
<td>Priest et al 2005 (63)</td>
</tr>
</tbody>
</table>
3. Natural antisense transcript (NAT)

The Human Genome Project offered a profound insight into how genomes are arranged and how little of its actual size consists of coding regions, suggesting that the complexity of life may not only lie within coding sequences. Technical improvements over the last decade led to the rather unexpected finding of extensive bidirectional transcription of eukaryotic genes. Some of these antisense transcripts result in pairs of sense and natural antisense transcripts that overlap and which maybe hybridise and even regulate each other’s expression (7).

Natural antisense transcripts or NATs are widely distributed throughout the human and mouse genome, but were first misinterpreted as transcriptional noise. The high number of NATs encoded in the genome suggests rather an evolutionary benefit from such a genomic arrangement. More evidence through high-throughput methods suggests a potential role of natural occurring antisense transcripts as transcriptional units like other regulatory RNAs (2).

3.1 Classification of NATs

Classification of NATs is related to their genomic location and their orientation to their corresponding sense transcript.

Classification according to their genomic location means that NATs are either in cis or trans. Cis-NATs are encoded on the same genetic loci and are perfectly complementary to the sense transcript. Trans-NATs are transcribed from different loci and are often shorter in size (5) and display an imprecise pairing with the sense transcript (3). A related class of transacting non-coding RNAs are microRNAs and snoRNAs (4). Another approach to classify NATs applies to the orientation of the antisense transcript in comparison to the sense transcript. Possible genomic arrangements are (A) head-to-head 5’-5’ or divergent NAT (B) tail-to-tail 3’-3’ or convergent NAT (C) fully overlapping and (D) non overlapping NAT (see Fig 3). Regarding their encoded information, NATs can be protein coding containing an open reading frame or non-coding, with both variants having different regulatory potentials (3).

The length of natural antisense transcripts varies strongly between a 100 bp up to several thousand base pairs with a minimum sense overlap of 20 bp (3, 7). NATs are tissue and cell
specifically expressed but their expression level is often relatively low in comparison with their corresponding sense transcript which makes them quite difficult to detect and amplify (5, 6).

3.2 NAT detection strategies and pitfalls

Defining what is the sense and which one is the antisense gene occurs based on several key points that define the sense and antisense genes. A) if both transcripts are encoding a protein or if one is non-coding then the non-coding refers to the antisense gene B) expression pattern, the higher expressed gene is the sense copy C) mostly but not only the sense mRNA undergoes splicing and has longer intronic sequences. Commonly used detection strategies to identify NATs are cDNA clones, EST libraries combined with exon – intron splicing sites and detection of poly a – tails. While the dominant fraction of NATs are nuclear restricted, non-coding and mostly not poly adenylated or spliced there are exceptions which are then excluded from detection methods using these criteria. Consequently the number of NATs is probably even higher than previously expected (5). Natural occurring antisense transcripts can also undergo splicing or arrive from intronless genes. Other pitfalls in detection of NATs and interpretation of high throughput screening and expression data arises also from varying NATs length for instance trans- NATs are commonly shorter (5). There is strong evidence that sense genes with an overlapping antisense transcript have a coordinated expression pattern which can be either positively or negatively regulated Fig.2. (5, 6, 7)

3.3 Antisense transcription

Approximately 15 to 20 % (1, 2, 5, 6 7) of all the coding mammalian genes and slightly less in plants (7) have an overlapping coding or non-coding natural antisense transcript (5). As NATs occur in such a high density throughout the genome then this implies an evolutionary benefit of such a genomic arrangement (7). However, the evolutionary conservation of the NATs may not be primarily on the sequence level, as non-protein coding NATs genes have a quite a low conservation (5). NATs are unequally distributed on the autosomes and X chromosomes, with underrepresentation of exonic overlapping NATs on the X chromosome which gives evidence to
evolutionary pressure on NATs. Regarding the common structural characteristics of NATs it points out that there is a conserved mechanism of regulation (6).

3.4 Functional and biological role of natural antisense transcripts

A clear advantage for RNA mediated transcriptional regulation is given by its quick production and degradation, its local storage, conformational flexibility, distribution, and its ability to interact with both nucleic acid and protein (5). Furthermore by using RNA transcripts as intermediate transport and information forms, cells can precisely direct spatial and local expression of proteins. Natural occurring antisense transcripts provide a new level of RNA based transcriptional regulation that is distinct from the already known epigenetic mechanisms of regulating transcription such as DNA methylation and histone acetylation (See Fig2).

3.4.1 RNA–antisense RNA interaction: RNA editing, RNAi and RNA masking

3.4.1.1 RNA editing

After being transcribed from the DNA strand, pre mature RNA undergoes a variety of maturation steps, such as 5’ capping, splicing and 3’ processing and polyadenylation (40). Another post transcriptional mechanism is RNA editing. Several different types of RNA editing (39) are known which alter the target mRNA sequence by a) addition or deletion of nucleotides or b) changing one nucleotide to another (40). The most popular form of this post transcriptional site specific alteration is the conversion from A-> I (Adenosine to Inosine) in dsRNA through an enzyme called ADAR (adenosine deaminase acting on RNA). Inosine base-pairs with cytosine and is functionally equivalent to guanidine (38).

Adenosine deaminase acting on RNA (ADAR). RNA editing occurs only in dsRNA although the length of the ds region that is targeted by editing can vary. Three different ADAR enzymes (ADAR1, ADAR 2 and ADAR3) are found in humans and are widely present throughout different tissues, except for ADAR3 which is only found in the CNS. Within a cell ADAR1 and ADAR2 have a specific subcellular distribution, ADAR1 and its 2 isoforms ADAR1L (long splicing transcript) found in the cytoplasm and ADARS (short splicing transcript)
present in nucleolus and nucleoplasm whereas ADAR2 is found only in the nucleolus. This distinct cellular distribution gives an idea of where the substrates they recognize are located \cite{40}. ADAR mutation or alterations in the RNA editing machinery are also linked to a various human diseases, such as depression, ALS, neuronal apoptosis and Dyschromotnosis symmetrica hereditaria \cite{38, 42}.

**RNA editing and natural antisense transcripts.** The biological role of RNA editing lies in fine tuning protein function, RNAi, modulating neuronal signals and control of microRNA function \cite{38,40}. Through RNA editing genetic diversity is created, one gene can give rise to a set of slightly different proteins while not abandoning the original one. But for one gene or mRNA to be edited by ADAR it must be present in a double stranded structure, either through forming a loop within its own structure or by nuclear duplex formation with its corresponding antisense transcript \cite{44}. Most of the reported A-to I editing sites are found in Alu repeats and long interspersed elements (LINES), which are mainly located in untranslated UTR regions of the mRNA \cite{40}. It was hypothesized that sense and antisense transcripts may form a nuclear RNA duplex that can serve as substrate for the RNA editing machinery, leading to the degradation, nuclear retardation or creation/destruction of splicing sites within the sense transcript \cite{1}. \textit{Rnp4f} gene and its correspondent NAT \textit{Sas10}, is a prominent RNA editing case reported from \textit{Drosophila melanogaster} where a sense antisense pair undergoes RNA editing \cite{44}. However there is no evidence yet supporting a role of RNA editing in human and mouse sense-antisense pairs \cite{1}.

### 3.4.1.2 RNAi

RNAi is a highly conserved response and defence mechanism against dsRNA that triggers sequence specific post transcriptional silencing. RNAi therefore acts as an antiviral defence, influences gene regulation and genomic stability, protects against transposons and inhibits genomic rearrangements during differentiation.

**SiRNA and miRNA.** Although they share one common feature i.e. their length (~20-24nt), siRNA and miRNA differ strongly in their origin and regulatory function. SiRNA derives from viral DNA and transposons and are transcribed by RNA polymerase II, and exported into the
cytoplasm. MiRNA derives from genomic sequences and are transcribed by RNA polymerase III. Pri-miRNA is processed by Drosha and also exported into the cytoplasm. In the cytoplasm an RNA III nuclease, DICER, binds to the dsRNA molecules, unwinds and cleaves them into small RNAs. The passenger strand is degraded, while the small RNA accumulates and is recruited by RNA induced silencing complex, RISC (53). RISC incorporates the ssRNA molecule and induces siRNA gene specific silencing. MiRNA can also induce gene specific silencing, while also target other genes at the same time, or regulate gene expression. SiRNA are homologous to their target RNA while for miRNA the degree of target complementarity determines its function, either as a silencer or a transcriptional regulator (40).

**RNAi and NATs.** It has been suggested that sense and antisense RNA duplexes may be processed by Dicer and mediate RNA induced silencing. Evidence for this RNAi mediated NAT mechanism is by now only proven to occur in *Arabidopsis* where salt tolerance is regulated by siRNA formation which is encoded by a pair of tail to tail overlapping sense and antisense pairs. But here both sense and antisense transcripts are coding for two stress related genes P5CDH (sense) and SRO5 (antisense). P5CDH is expressed under normal physiological conditions. Due to altered salt concentration the transcription of SRO is induced leading to duplex formation of sense and antisense transcripts and down regulation of P5CDH through cleavage of its mRNA. There have not yet been any reported cases of RNAi- NAT mediated regulatory mechanisms in mammals. (1).

### 3.4.1.3 RNA masking

Unlike RNA editing that occurs in the nucleus, RNA masking takes place in the cytoplasm (44). Sense and antisense RNA or more general ssRNA folds up into hairpin structures and masks binding sites for transcription factors or miRNA, splicing sites or influences the stability and translation of the sense mRNA (1).

**Prominent examples for RNA masking.** BACE1 (β site - amyloid precursor protein cleaving enzyme) which is involved in Alzheimer’s disease, shows an increased stability when its corresponding antisense transcript is present (8). Through duplex formation with BACE1 antisense transcript, a miRNA binding site is masked (45). Another well studied example of
RNA masking is the HIF (hypoxia inducible factor) that is activated due to low oxygen conditions. Two main splice variants of HIF-1α and HIF-2α are known, they show distinct functionality during embryogenesis (46). The expression of HIF1-α antisense transcript alters the mRNA stability of one splicing variant dramatically by altering its 2nd structure and exposing an Alu rich element and leading to its decay (44, 45). Recent findings discovered that p53, the main tumour suppressor and guardian of the genome whose loss of function is a major cause of cancer, has a corresponding antisense Wrap53. Wrap53 stabilizes p53 mRNA leading to an increase in both mRNA and protein levels of endogenous p53. Protein levels are enhanced by Wrap53 targeting the 5’ untranslated region and marking it for siRNA RNA masking which results in correlated expression levels of sense and antisense transcript (1) See figure 2 (B).

3.4.2 DNA–RNA interactions: transcriptional interference, epigenetics

3.4.2.1 Transcriptional interference

Transcriptional interference is based on the assumption that transcription occurs only in one direction at a given time (44). As sense and antisense transcripts are encoded on opposite strands, RNA Polymerase II simultaneously transcribes from each strand but the transcriptional apparatus might collide in the overlapping regions (1). Transcriptional interference leads to either a non-correlated, inverse expression pattern or a complete stop of transcription on both strands. A study on the effect of length and type of the overlap of sense-antisense genes on their expression level found a correlation. The length of the overlapping regions that were up to 200bp showed the highest sense and antisense co-expression whereas co-expression decreased to zero at overlapping lengths >2000bp. This proves the longer the overlap the more likely is transcriptional collision. Head to head, tail to tail and fully overlapping are the three types of orientation of sense and cis NATs. The way they are oriented to each other has also an impact on their expression level like length does. Head to head orientation and fully overlapping NATs show a decreased co-expression pattern than tail to tail sense–antisense orientated NATs (47).

Prominent examples of transcriptional interference: Gal7 and Gal10.
Due to transcriptional collision of RNA Polymerases II in the overlapping area, sense and antisense transcripts exhibit an inverse expression pattern see fig2 (A) (1). What is still controversial is the role of transcriptional interference as the main regulatory mechanism for NATs. First this approach requires that sense and antisense RNA are transcribed simultaneously from only one allele. This is often not the case either and the time point of transcription can vary between sense and antisense transcripts or the transcript from different alleles, maternal or paternal. This might explain why the X chromosome shows relatively low levels of antisense transcription (i.e. gene dosage, one X chromosome is inactivated) (44).

3.4.2.2 Chromatin remodelling and epigenetics

Chromatin remodelling is induced by altered methylation, acetylation or phosphorylation states leading to chromatin decondensation or condensation, which makes certain genes accessible or inaccessible for transcription. It has been suggested that NATs play a role in DNA methylation by directly interacting with methylases or influencing chromatin modifications of non-imprinted autosomal genes by recruiting histone modifying enzymes (44). The proposed mechanisms by which NATs alter expression and influence chromatin condensation, is through suppressing transcription of the sense gene by binding to its promoter region and in a 2nd instance recruiting histone remodelling enzymes, like deacetylases and methylases (1, 44). Several well characterized cases of NAT mediated transcriptional silencing are reported, where binding of antisense to regulatory DNA sequences induces trimethylation and heterochromatin formation see fig 2 (D).

For example, CDKN1A (p21) encodes for a cyclin dependant kinase inhibitor which is a well-known tumour suppressor gene that is regulated by its corresponding antisense transcript. CDKN1A antisense expression recruits and mediates trimethylation at the sense promoter region. Highly interesting in this case, is that a synthetic 21bp long dsRNA targeting the p21 promoter region causes a phenomenon described as RNAa (RNA activation) leading to p21 expression (52).

Through Dicer k. o. studies, where heterochromatin formation was drastically impaired, it was proposed that RNAi and chromatin remodelling might work in concert (51). More
evidence supporting a role for NATs in epigenetics is based on the finding that chromatin binding enzymes have conserved RNA binding motifs, giving rise to the idea that NATs are local modulators of chromatin remodelling enzymes. Another very interesting aspect is that NATs have a relatively low expression level but their impact on sense expression can be dramatic, suggesting epigenetics as a central mechanism of NAT mediated transcriptional regulation due to its low copy number requirements. There are only two alleles of each gene in a given healthy cell, if NATs directly interact with DNA, then theoretically only 2 NAT copies per cell would be required to suppress or modulate gene expression (44). Moreover, antisense expression reaches its peak before and during recombination and is believed to induce opening up of chromatin structures during recombination (1).

**Genomic imprinting** describes the phenomenon of an inherited monoallelic expression, where either the maternal or paternal allele of a gene is expressed. Around one hundred and sixty imprinted genes are reported most of which are found in small clusters (53). For several cases of genomic imprinted genes, chromatin remodelling and DNA modifications are induced by natural antisense transcripts (6, 7, 8, 44).

**Prominent example: X chromosome inactivation.** X chromosome inactivation is required to regulate gene dosage in female mammals. First during an early stage of embryonic development, only the paternal X chromosomes are inactivated which is reversed in the early blastocyst. One of the two inherited paternal or maternal X chromosomes will be randomly inactivated during embryogenesis. X inactivation, the transition from eu- to heterochromatin that is firmly packed, is controlled by the Xic (X inactivation centre) where four non protein coding genes are found. The Xic is crucial for X inactivation and encodes Xist, Tsix, Jpx and Ftx. Xist, a long non coding RNA is weakly expressed from both X chromosomes but is relatively unstable (50, 44). Due to changes of either stability or to sex specific induction of transcription the expression level of Xist increases from the prospective inactive chromosome, Xist spreads, binds and coats the future inactive chromosome (55). Further Xist coating recruits histone methylases and leads to chromatin condensation (1). On the same locus, on the opposite strand, downstream of Xist a natural antisense transcript Tsix is encoded. Tsix is a non-coding 40 kbp long, nucleus restricted RNA that is also weakly expressed from both chromosomes before onset of X inactivation (50). While
the inactive X chromosome enhances Xist expression, the remaining active X chromosome increases the expression of its antisense gene Tsix (1).

Although it is still not fully understood through which exact mechanism natural antisense transcripts influence chromatin remodelling, in most cases the expression of a whole cluster of genes is altered. For chromatin remodelling, an inverse expression pattern between antisense transcript and all genes in the cluster is predicted (1) see fig 2 (D)

**Fig.2 Left: OVERVIEW: Possible regulatory mechanisms by which NATs can influence expression levels of corresponding sense transcripts.** Mechanism of antisense action (A) Transcriptional interference (B) Alternative Splicing (C) RNA editing and RNAi (D) Chromatin remodelling **Right:** Relationship between sense and antisense mRNA levels (1)

4. **SCN9A and its corresponding antisense transcript**

The human and mouse SCN9A/Scn9a sense genes both have a corresponding antisense transcript organised into a tail to tail arrangement (i.e. 3’ ends overlapping). The sense-antisense overlapping region in human is approximately 500 bp while in mouse it is around
180bp. Both antisense transcripts in mouse and in human are non-protein-coding and have a total length of 2352bp and 1347bp respectively.

**Fig.3** Natural antisense transcripts and sense transcript can have four different genomic arrangements: head-to-head 5’-5’, divergent NAT (B) tail-to-tail 3’-3’, convergent NAT (C) fully overlapping (D) no-overlapping. A: Tail-to-tail arrangement of human Nav1.7 antisense gene (BC051759) and SCN9A on chromosome 2 (genome uscs) (B) tail to tail arrangement of the mouse SCN9a antisense gene on chr.2. Size of the sense-antisense overlapping region for mouse ~180bp while for human ~500bp.
5. **Material and Methods**

5.1 **Gels, LB and Plates**

5.1.1 **Agarosis gel** 0.9 %, 1.62 g agarosis in 180ml 1x TAE Buffer

5.1.2 **1kb Ladder Invitrogen see appendix AP 1.1**

5.1.3 **100bp Ladder Invitrogen see appendix AP 1.2**

5.1.4 **LB** 10 g LB broth in 500ml ddH2O. Mixed by hand and autoclaved for 20 min at 121 degrees

5.1.5 **LB Agar** 10 g LB and 7.5 g Agar broth in 500 ml ddH2O autoclaved for 20 min at 121 degrees and cooled down to ~42 C

5.1.6 **Antibiotics added to LB or LB+Agar** Ampicillin (100ug/ml) or Kanamycin (25ug/ml)

5.2 **RNA isolation**

Deeply anesthetize mice with CO₂ and terminate through neck breaking, dissect DRGs, and bring freshly dissected DRGs into RNAlater (Qiagen 11560622) or dissection medium. Remove nerve strings and store for maximum one week in RNAlater at 4C.

- **Dissection medium:** HBSS w/o Ca2+and Mg2+, HEPES (Gibco 15630-049) 5mM, Glucose 10mM (Sigma)

Clean glass homogenizer by washing with tap water and 1 time with RNaseZap (Ambion 9782) and three times with 1 ml of DEPC-treated water. Finally wash glass homogenizer with 0.5 ml of TRIzol. Add 0.6 ml TRIzol (Invitrogen 15596-026) into homogenizer and transfer dissected DRGs into the glass homogenizer. Mixture is left incubating 3-5 minutes at room temperature. DRGs and TRIzol are carefully homogenised by hand for at least 1-2 min but maximum 3 minutes. Sample volume of approximately 700ul is brought onto a QIAshredder mini column (Qiagen 79654). Spin full speed at 13k rpm for 2 min, column is removed and supernatant is centrifuged for another 3 minutes at full speed. Transfer supernatant into PLG tube (Phase-lock Gel, heavy (VWR 713-2536)). Spin at ~16,000xg for 20 seconds before use. Measure the volume of supernatant with a pipette. 2/10th of sample volume of chloroform is added to the sample (or chloroform isopropanol alcohol 24:1). Mixture is shaken vigorously by hand for 15 seconds and left to stand for 3 min. Spin (~16,000xg) for
15 min at 4°C. Carefully remove the upper colourless aqueous layer using a p10 tip to recover the final drop, and place into a fresh 1.5ml tube. Measure the volume of this aqueous phase with a pipette. Slowly add an equal volume of 70% ethanol to the aqueous phase. Gently mix by pipette and transfer the sample to an RNeasy MinElute spin column (Qiagen 74204) place in a 2 ml collection tube. Close the lid and spin for 15 seconds at 16,000xg. Discard the flow-through. Place the RNeasy MinElute spin column in a new 2 ml collection tube. Add 500 µl Buffer RPE to the spin column. Close the lid and spin for 15 seconds at 16,000xg. Discard the flow-through. Pipette 80 µL of the DNase I/Buffer RDD mix onto the membrane, leave at RT for 15min. Close the lid and spin for 15 seconds at 16,000xg. Discard the flow-through. Add 500 µl Buffer RPE to the spin column again. Close the lid and spin for 15 seconds at 16,000xg. Discard the flow-through. Add 500 µl 80% ethanol to the spin column. Close the lid and spin for 15 seconds at 16,000xg. Discard the flow-through. Put the RNeasy MinElute spin column in a new 2 ml collection tube. Open the lid of the spin column, and spin at full speed for 5 min, put the RNeasy MinElute spin column (Qiagen 74204) in a new 1.5 ml collection tube. Add RNase-free water (Invitrogen) directly to the centre of the spin column membrane. Close the lid gently, and spin for 2 min at full speed to elute the RNA. Measure the RNA concentration with Nanodrop and store at –80 degrees.

5.3 Cloning, Kits and PCR

5.3.1 OneShot© Top10 chemically competent cells (Invitrogen C4040-10)
For protocol see Appendix AP1.3

5.3.2 XL10-Gold ultracompetent Cells (Stratagene C- 200314).
For protocol see Appendix AP1.4

5.3.3 Miniprep (Qiagen Spin Miniprep kit). For protocol see appendix AP1.5

5.3.4 Maxiprep protocol see appendix Qiagen High speed Maxiprep kit. For protocol see Appendix AP1.6

5.3.5 Gel purification see appendix AP1.7 Qiagen Gel purification kit

5.3.6 PCR Purification Qiagen see Appendix AP1.8

5.3.7 DreamTaq Green DNA polymerase kit AP 1.16
5.4 Restriction digests

- **Single Digest**: 15 µL of H$_2$O, 2 µL of appropriate restriction enzyme buffer, 2 µL of DNA (200 ng), 1 µL of restriction enzyme. Leave 3 hours at 37°C or 65 °C.

- **Double Digest**: for 2 restriction enzymes, use 1 µL of each enzyme with 2 µL of buffer, 2 µL of DNA (200 ng) and 14 µL of H$_2$O.

*Enzymes used EcoRI, BamHIII, BstBI, BsaAI, KpnI, HindIII (New England Biolabs)*

5.5 SuperScript RT (Invitrogen) see Appendix AP 1.9

5.6 Phusion high fidelity PCR kit, Finnzymes F-553S/L protocol see Appendix AP 1.10

5.7 Ear DNA Extraction for PCR – Isolation of Genomic DNA

Collect ear tissue in 0.5 ml tube using an ear puncher. If not extracting DNA immediately, store tissues in freezer. Prepare enough lysis mixture for all samples plus a bit extra (i.e. if you have 10 samples, make up enough for 11). The lysis mixture consists of PCR lysis buffer and Proteinase K 1/500 dilution. Add 30 µl of this lysis buffer mixture to each tube. Place tube in PCR machine and incubate at 55°C for 1 h. Vortex halfway through the incubation to facilitate lysis. Incubate at 95°C for 5 min to de-activate proteinase K. Add 30 µl of distilled water and vortex for 30 s. Spin at 12,000 rpm for 1 min. Use 1 µl of supernatant per PCR reaction. Store the DNA sample at -20°C.

*PCR Lysis Buffer (stored at -20°C) 10X GB, 25% TritonX-100, beta-mercaptoethanol, H2O10X GB (store at -20°C) 1.5M Tris pH8.8, 1.0 M (NH4)2SO4, 1.0 M MgCl2, H2O*

5.8 Mouse Total RNA Master Panel

Mouse total RNA master Panel (Clontech 636644 see Appendix AP1.11). Total RNA from BALB/c m/f mice isolated by a modified guanidinium thiocyanate method. Total RNA from 15 different samples of tissue and developmental stage specific RNA with a concentration of 1µg/ul. Total RNA is transcribed into cDNA with SuperScript (see 5.5) and cDNA is used as a template for PCR with proofreading DNA Polymerases Phusion (see 5.3.7). Additionally one sample of black6 mice DRG cDNA (Black6 DRG) =110ng/ul is added to the mouse Total RNA master panel.
Primers for mouse tissue panel are chosen due to their efficiency in previous PCR reactions. Neat template is diluted ¼ in H20.

**Nav1.7 sense primers** M1.7 RXN 6 FWD 5’-GGCAAACGTGACATCAGGATTTTG-3’, M1.7 RXN 6 REV5’-TGTAACAGGTATCCAAACGAAGC-3’ expected size 1375bp, which were also used during the RNA editing project. **Nav1.7 antisense primer**: M1.7 AS 1 FWD 5’-GAACAGGTCTTGTTCCTCG, M1.7 AS 1 REV5’CCACGCTTGTTCCTAGAGC-3’ expected size 625bp. **Housekeeping Gene HPRT1**: FWD 5’-GATGATGAACCAGGTATGACC-3’, REV 5’-TTTCCAGTTCACACTAGAC-3’ expected size 605bp

PCR reactions were performed with proofreading DNA polymerases – i.e. Phusion (see 5.3.7)

ThermoCycling condition: Annealing temperature (Ta)
Ta (M1.7RXN 6) =63.3 C, 35 cycles; Ta (M1.7 AS 1) =63.5 C, 30 cycles; Ta (HPRT1) =55C

30 cycles; PCR with Phusion is performed at an annealing temperature +3C above the Tm of the primer used during PCR.

5.9 VECTORS

5.9.1A Cloning of human full length antisense transcript

Human, **BC051759**, cloning of the whole BC051759 sequence from a bought cDNA: IMAGE Human CDNA clone, BC051759 Clone ID 5582690. CDNA Image Human Clone arrived in a glycerol stock and was plated out onto LB Amp plates. Following incubation overnight, single colonies were inoculated into 5ml liquid LB + Ampicillin. DNA was then isolated using Miniprep protocol and used as template in PCR using Phusion. To obtain enough antisense transcript for cloning into pcDNA3 expression vector, at least 8 identical PCR reactions were started. Primer: Human AS HINDIII FWD 5’-CCCAAGCTTGTCTTAGTCCTCTGAATTTT-3’, Human AS KpnI REV5’-CGG GGTACC CCA ATTGATGGAGAATTTTAT-3’ expected size of the PCR product 2302bp.

PCR reactions were loaded on a 0.9% agarosis gel and bands cut out under UV and pooled for gel purification. Human Nav1.7 full length antisense sample concentration measured via Nanodrop: c (H1.7AS): 98.4 ng /ul eluted in 40 ul Elution Buffer (Qiagen) (used as stock).
**Fig 5.9a Human** (A) Amplification of full length antisense sequence from a cDNA clone using specific primers with integrated restriction sites. (B) Double restriction digest with KpnI and HindIII

### 5.9.1B Cloning of mouse full length antisense transcript

The mouse full length antisense transcript was cloned using a mouse cDNA clone as template (AK138532) (Fantom CDNA clone [http://www.dnaform.jp/products/fantom/pd^f/FANTOM-PX-PY-PZ.pdf](http://www.dnaform.jp/products/fantom/pd^f/FANTOM-PX-PY-PZ.pdf)) (see Appendix AP1.12). The cDNA clone stock (5 ng) was plated out onto LB+AMP plates and incubated o/n at 37 degrees. The following day, single colonies were inoculated into 5ml liquid LB + Ampicillin. DNA was then prepared using a Miniprep protocol and used as template in PCR using the Phusion proofreading DNA polymerase. To obtain enough antisense transcript for the following cloning step into pcDNA3, at least 8 identical PCR reactions were performed using the proofreading DNA Polymerase Phusion. Primer sequences: Mouse full-length antisense HindIII FWD 5’-CCCAAGCTT GAGCAAGAGT AAGAAGTA-3’, Ms AS KpnI REV 5’- CGGGGTACC GCCATTATATTTCAT-3’, expected size 1347bp (full length antisense cDNA sequence see supplemental data 2). PCR reactions were loaded onto a 0.9% agarosis gel and bands were cut out under UV and pooled for gel purification. Mouse Nav1.7 full length antisense sample concentration measured via Nanodrop: (Ms Nav1.7): 46.5 ng /ul eluted in 40 ul Elution Buffer (Qiagen)

**For Both 5.9.1A and 5.9.1B**
As the human and mouse full length antisense transcripts are non-coding and not translated into protein, precise cloning of the antisense transcript with as few as possible additional bases is required. Therefore human and Mouse full length antisense primers are designed to include specific restriction sites that map to the 5’ end of the multiple cloning site to reduce the number of additional bases that could be transcribed from the pcDNA3 expression vector. Restrictions sites integrated into the primer sequence were chosen according to RestrictionMapper (http://www.restrictionmapper.org/). Browsing of both human and mouse SCN9A antisense transcript cDNA gave KpnI and HindIII as optimal cutters as they do not cut within the antisense transcripts but have cutting sites towards the 5’ end of the multiple cloning site of pcDNA3.

![Image of gel](image_url)

**Fig5.9b Mouse** (A) Amplification of full length antisense sequence from cDNA clone using specific primer with integrated restriction sites. Clear and strong band are visible on the gel

5.9.2 Expression vector

pcDNA3 (Invitrogen see appendix), empty vector size 5.4kb, sample concentration 2ng / ul *(Fig 5.9c)* with multiple cloning sites *(for full description see appendix AP 1.13)*. Both pcDNA3 vector and full length human/mouse Nav1.7 antisense transcript are double digested O/N at 37 degrees with KpnI and HindIII. Double digest conditions for HindIII and KpnI are chosen according to http://www.neb.com/nebecomm/DoubleDigestCalculator.asp for Double Digest Finder.
Digestion for 3 hours at 37 degrees in H2O, Buffer NEB 2, BSA for optimal digesting conditions. To verify that the double digest was successful, both the vector and the antisense samples are loaded on a 0.9% agarosis gel and cut out under UV.

Concentrations human H.1.7 AS = 43.8 ng/µl and Vec 1 = 110.5 ng/µl.

![Full length cDNA human/mouse antisense transcript](image)

**Fig 5.9c** pcDNA3 Vector with MCS (multiple cloning sites) and full length human /mouse Nav1.7 antisense cDNA integrated between HindIII and KpnI. Full length Nav1.7 antisense transcript mouse: 1380bp, cDNA full length Nav1.7 antisense transcript human: 2302bp

Nav1.7 antisense transcript human/mouse is gel purified and has the final concentration after gel purification: Vec2 = 131.4 ng/µl; Mouse Ms1.7 AS = 16.9 ng/µl and Vec1 = 119.3 ng/µl, Vec2 = 102.5 ng/µl.

### 5.9.2.2 SAP TREATMENT OF pcDNA3 ONLY

Linearized pcDNA3 Vector is treated with SAP (**see Appendix AP 1.14**).

10 µl Vector / 0.5 µl SAP incubation for 40 min at 37 degrees and 20 min for 72 degrees.

### 5.9.2.3 Ligation of full length NAV1.7 antisense transcript to pcDNA3 vector.

Equation to determine best vector: insert ratio for ligation.

\[
\text{Vector (ng)} \times \text{insert size (kb)} \times 3:1 \text{ or } 5:1 \text{ ratio} \times \text{Size of vector (kb)}
\]
Table 1: Ligation approaches human Nav1.7 antisense expression vector

<table>
<thead>
<tr>
<th>Ratio</th>
<th>Vector (Vec2)</th>
<th>Insert (44ng/ul)</th>
<th>H20</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:1</td>
<td>10ng(0.76ul)</td>
<td>50ng(4.84ul)</td>
<td>Up to 17 ul</td>
</tr>
<tr>
<td>3:1</td>
<td>10ng(0.76ul)</td>
<td>30ng(2.90ul)</td>
<td>Up to 17 ul</td>
</tr>
<tr>
<td>1:1</td>
<td>10ng(0.76ul)</td>
<td>10ng(0.97ul)</td>
<td>Up to 17 ul</td>
</tr>
<tr>
<td>Plus ligase</td>
<td>10ng(0.76ul)</td>
<td>x</td>
<td>Up to 17ul</td>
</tr>
<tr>
<td>No ligase</td>
<td>10ng(0.76ul)</td>
<td>x</td>
<td>Up to 17ul</td>
</tr>
<tr>
<td>Neg control</td>
<td>x</td>
<td>x</td>
<td>Up to 17ul</td>
</tr>
</tbody>
</table>

Table 2: Ligation approaches mouse Nav1.7 antisense expression vector

<table>
<thead>
<tr>
<th>Ratio</th>
<th>Vector (Vec2)</th>
<th>Insert (16.9ng/ul)</th>
<th>H20</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:1</td>
<td>10ng(0.83ul)</td>
<td>50ng(7.52ul)</td>
<td>Up to 17 ul</td>
</tr>
<tr>
<td>3:1</td>
<td>10ng(0.83ul)</td>
<td>30ng(4.51ul)</td>
<td>Up to 17 ul</td>
</tr>
<tr>
<td>1:1</td>
<td>10ng(0.83ul)</td>
<td>10ng(0.70ul)</td>
<td>Up to 17 ul</td>
</tr>
<tr>
<td>Plus ligase</td>
<td>10ng(0.83ul)</td>
<td>x</td>
<td>Up to 17ul</td>
</tr>
<tr>
<td>No ligase</td>
<td>10ng(0.83ul)</td>
<td>x</td>
<td>Up to 17ul</td>
</tr>
<tr>
<td>Neg control</td>
<td>x</td>
<td>x</td>
<td>Up to 17ul</td>
</tr>
</tbody>
</table>

Ad table 1 and 2: control reactions (1) Plus ligases was used as background control
(2) No ligases determine the degree of undigested vector pcDNA3 (3) negative control with H20 instead of insert determines general contamination

- Ligation Mix: T4 Ligase (Fermentas), T4 ligase Buffer (Fermentas), H20. Ligation Master Mix is added, followed by 1 hour incubation at 22 degrees. At this point reactions can be stored at – 20 degrees.

5.9.2.4 Transformation of human/mouse antisense ligations into chemically competent E.coli cells
Transformations were plated out onto LB/Agar + Amp plates and incubated O/N at 37 degrees. Transformation protocol for see XL10 – Gold ultracompetent cells.

On the water negative control plates no colonies were visible. A few colonies appeared on the plates with “no Ligases” and “plus Ligases”. Ten single colonies were picked from positive 3:1, 5:1 plates and inoculated into 5 ml LB+Amp and incubated O/N shaking at 220 rpm at 37C. The bacterial cells were harvested by centrifugation at 5000 rpm for 10 min, and supernatant was discarded while the pellet contains the amplified expression vector. This step is followed by Miniprep and double restriction digests (Fig 5.9.a) with HindIII and Kpnl to check for positive colonies that have inserted the full length antisense transcript into the vector.

Gel purification (see 5.3.5) of the positively transformed samples. As our gene of interest was already positively inserted into the vector, 2 chosen samples were re – transformed into XL-10 Gold ultracompetent cells (Invitrogen, see 5.3.1) and plated on LB+Amp plates and incubated O/N at 37 C. Single colonies from the LB+Amp plates were brought into a 5 ml LB +amp day culture, and let to grow shaking 250rpm for approximately 7 h at 37 C. Day cultures were then transferred into Maxiprep cultures, 500 ml LB +amp, incubated O/N, shaking at 250 rpm at 37 C and then Maxiprepped (Qiagen, high speed Maxiprep see 5.3.4). DNA was eluted in 1ml Elution Buffer EB and concentrations measured using Nanodrop: Human (EXPH1) = 413 ng/ul; Human (EXPH2) = 345 ng/ul; Mouse (EXPM1) = 204 ng/ul; Mouse (EXPM2) = 276.3 ng/ul.

To ascertain that there were no rearrangements or deletions of the full length (A) human (B) mouse full length SCN9A antisense transcript vectors, double digest with Kpnl and HindIII was performed (Fig 5.9e). 5 ul of each samples were loaded onto 0.9% agarosis gels.
**Fig 5.9e Double Digest with KpnI and HindIII after Maxiprep** to check that the expression vector constructs have positively integrated our insert of interest (A) human (B) mouse full length SCN9A antisense transcript.

Samples that contain the full length human/mouse antisense transcript according to the right size on the analytical gel are diluted in EB to a concentration of 110ng/ul for sequencing with primers (for mouse *(see mouse antisense primers 5.10.1.3)* and for human *(see human antisense primer 5.10.2.3)*). Primers are chosen and designed to give partially overlapping sequences of full length human/mouse SCN9A antisense transcript.

### 5.9.2.5 Sequencing - Bioinformatics

Sequencing results of each partial sequence were individually compared against reference sequence databases using the Genome UCSC *(http://genome.ucsc.edu/)* and NCBI BLAST *(http://blast.ncbi.nlm.nih.gov/Blast.cgi)* web tools. Nucleotide blast (Data base: Reference genomic sequences (refseq_genome), organism: mus musculus taxid: 10090 or Homo sapiens taxid: 9606) identified the sequenced inserts as full length human BC051759 and mouse AK138532 full length SCN9A antisense transcripts. Expression vectors are stored at -20C.

### 5.9.3 Additional vectors: pEGFP

pEGFP vector has the size of ~ 3.4kb and encodes for a red shifted variant of a wild type GFP (AP 5.9.4), GFPmut1 with an excitation maximum at 448 nm and emission maximum at 507 nm *(Fig 5.9f)*. For full information on pEGFP vector with MCS and additional features see Appendix AP1.15 *(or http://www.pkclab.org/PKC/vector/pEGFPN1.pdf)*
Fig 5.9f (A) EGFP vector with and restriction map and MCS

5.10 Primer mouse Nav1.7 sense and antisense transcript

5.10.1.1 Primer mouse Nav1.7 Antisense transcript

**M1.7 AS1** FWD 5'-GAACCAGGTCTTGGTTTTCTG -3’, REV 5’-CCACGCTTCTCCTAGAGC-3’
Size 625bp;

**M1.7 AS2** FWD 5’-GGAAGGGACATCATCAGAGC-3’ REV 5’-TCATTTTAATGAATCAAGCCTTA-3’ size 908 bp

**M1.7 AS3** FWD 5’-GATCAGGCGTAGGATTCGTC -3’, REV 5’-CATAGACACTGCGTGCTGCT-3’, size 624bp

**M1.7 AS4** FWD 5’-GCACGACTTCTCCTGCTGCTGCT -3’, REV 5’-CARAGACACTGCGTGCTGCTGCT -3’ size 879bp

5.10.1.2 Full length SCN9A antisense transcript

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence 5’-3’</th>
<th>Size</th>
<th>Tm</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS HindII FWD</td>
<td>CCCAAGCTT GAGCAAGAGT AAGAAGTA</td>
<td>1347bp</td>
<td>61.4</td>
</tr>
<tr>
<td>MS KpnI REV</td>
<td>CGG GGTACC GCCATTATATTTCAT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5.10.1.3 SCN9A sense - sequencing
<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence 5′- 3′</th>
<th>Size</th>
<th>Tm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Runs from M1.7 RXN 1 FWD</td>
<td>CTCTTAGGTAAGGATCCGAAGGGG</td>
<td>1004 bp</td>
<td>69</td>
</tr>
<tr>
<td>M1.7 RXN 1 REV</td>
<td>GAAACCGAAAGGAGAGCATCTTG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coding sequence</td>
<td>NM_018852 1365-2616</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1.7 RXN 2 FWD</td>
<td>ATAAATGTTTCCGGAAGGACCTTG</td>
<td>1251 bp</td>
<td>68</td>
</tr>
<tr>
<td>M1.7 RXN 2 REV</td>
<td>ACTGTGTTGTTAGAATGCTTGCT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coding sequence</td>
<td>NM_018852 2447-3657</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1.7 RXN 3 FWD</td>
<td>GGACCCCTAGCCCTCATGCT</td>
<td>1210 bp</td>
<td>72</td>
</tr>
<tr>
<td>M1.7 RXN 3 REV</td>
<td>CTTATCTCGCAAGGTACGTTTG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Runs from M1.7 RXN 4 FWD</td>
<td>TCCAAAAAGCCAAAGGGCTCCA</td>
<td>1096 bp</td>
<td>67</td>
</tr>
<tr>
<td>M1.7 RXN 4 REV</td>
<td>GCACATTTCCACTAACATTTACAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Runs from M1.7 RXN 5 FWD</td>
<td>TGTGTTAACACCACAGATGCTCT</td>
<td>701 bp</td>
<td>69</td>
</tr>
<tr>
<td>M1.7 RXN 5 REV</td>
<td>AAATCAAAAAATGTCCATCCCCACG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Runs from M1.7 RXN 6 FWD</td>
<td>GGCAAACTGACTACATGAGTTTTG</td>
<td>1375 bp</td>
<td>65</td>
</tr>
<tr>
<td>M1.7 RXN 6 REV</td>
<td>TGTAACAGTGATCAAACCGGC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5.10.1.4 Additional Sequencing Primer

**T7** 5′- TAATACGACTACCTATAGGG-3′,  **SP6** 5′- TACGATTGTTAGGTACACTATAG-3′

5.10.1.5 Mouse tissue panel

**Sense:** M1.7 RXN 6 FWD 5′-GGCAAACTGACTACATGAGTTTTG-3′,
M1.7 RXN 6 REV 5′-TGTAACAGTGATCAGAGGGTACACTATAG-3′

**Antisense:** M1.7 AS 1 FWD 5′- GAACGGTCTGTGCTTTTG-
M1.7 AS 1 REV 5′- CCAGCGTCTGAGAAGGCTAGAGC-3′

**Housekeeping gene HPRT 1:** FWD 5′- GATGATGAACCAGGGTTACGACACTATAG-3′,
REV 5′ –TTTCCAGGTCACTATGACAC-3′
5.10.2 Primer human Nav1.7 sense and antisense transcript

5.10.2.1 Primer Human BC051759 antisense transcript: full list

**H 1.7 antisense 1** FWD 5’-GGAATTCAGGCAAAGTTGGA-3’, H 1.7 antisense 1 REV 5’-CACCAACATTCCAGCCATTGG-3’ size 991bp

**H 1.7 antisense 2** FWD 5’-GGATCACTCGGAACAGGGTA-3’, H 1.7 antisense 2 REV 5’-CACCAACATTCCAGCCATTGG-3’size 819bp

**H1.7 Primer set 1** FWD 5’- CACCAGCGACCAGAAGTGA-3’, H1.7 Primer set 1 REV 5’-AGGGAGTGACGCACAAAAAC-3’ size 1572

**H1.7 Primer set 2** FWD 5’-GCCTCAAGTGATCCTTCTGC-3’, H1.7 Primer set 2 REV 5’-TTTTCTCACTGGGAGATCTGC-3’ size 2000bp

**H1.7Primer set 3** FWD 5’-GTGGAGTGACGTACAGTGCA-3’, H1.7Primer set 3 REV 5’-AGGGAGTGACGCACAAAAAC-3’ size 1017

5.10.2.2 Full length SCN9A antisense transcript

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence</th>
<th>Size</th>
<th>Tm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hm HindIII FWD</td>
<td>CCAAGCTTGCTTAGCTCTGTAATATTGT</td>
<td>2302bp</td>
<td>58.5</td>
</tr>
<tr>
<td>Hm KpnI    REV</td>
<td>CGGGGTACCCCAATTGGAGAATTTAT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5.10.2.3 Sequencing primer

T7 5’- TAATACGACTCAGATATAGGG-3’, SP6 5’-TACGATTTAGGTGACACTATAG-3’

BC05179XX FWD 5’-GACTTTTGAGTAATCATGGA-3’

5.11 Cell culture

All cell culture work (e.g. cell splitting, media preparation, transfections and coverslip coating) are performed under a previous EtOH sterilized hood to ensure maximum sterility.

Lab coat and gloves sterilized with EtOH must be worn at all times.

5.11.1 Cell Lines
HEK 293 cells that stably express Nav1.7 were generated by stable co transfection of HEK 293 cells with an alpha subunit and a beta1 subunit of human sodium channel 1.7 (Scottish Biomedical).

HEK 293 Nav1.6 L40 cell line was generated by stable co transfection of HEK 293 cells with an alpha subunit and a beta1 subunit of human sodium channel 1.6 (Scottish Biomedical).

5.11.2 Cell culture media – MG

MEM (Sigma M5650), 2mM L- Glutamine (Sigma G7513), 10% FBS Heat inactivated (Invitrogen 2011-11), 2ug/ml Blastocydin (calbiochem 203350), 0.6mg/ml Geneticin (Invitrogen 10131-027), 10ml/L Penicillin –streptomycin (Sigma P0781). All reagents were filtered under the lamina through Stericup/Steritop filter (Millipore) to avoid contamination.

5.11.3 Cell splitting

Aspirate media and incubate with trypsin for ~2-3 minutes. Aspirate trypsin and resuspend in 10 ml of culture media MG Nav1.7 stable and wash off the cells. Transfer suspension into 15ml tubes and centrifuge 5 min at 800rpm. Aspirate supernatant and resuspend cell pellet in 10 ml MG stable cell media. Cells are split into 2ml dishes or a flask. Best transfection results are obtained with cells at around 90 per cent confluence on the day of transfection.

5.11.4 Coating

Both BD Matrigel (BD Biosciences) and DMEM (Sigma M5650) need to be permanently kept on ice. 200ul Matrigel is added to 20ml filtered DMEM without FBS (Invitrogen 2011-11). After gently mixing the reaction 300ul of the mixture is added to coverslips in a 24 well plate and incubated for 30 minutes at RT. Aspirate excessive Matrigel and replace with 500 ul cell suspension, placed onto each coated coverslip/well.

5.11.5 Transfection

5.11.5.1 Transfection of Nav1.7 stable expressing cell line for immunohistochemistry
Nav1.7 cells with an approximately 90% confluence were transfected with (1) no DNA (2) EXPH1, pcDNA3 vector containing full length human SCN9A antisense transcript. 

**Concentration:** (EXPH1) = 413 ng/μl; According to the manufacturer’s protocol, DNA was mixed with Lipofectamin in a 1:2.5 ratio.

Transfection solution was slowly and drop wise added to the Nav1.7 cells and incubated for 6 h at 37°C /5% CO2. After 6h the transfection solution was aspirated and replaced with MG stable cell culture medium (see 5.11.2). Cells were incubated at 37°C / 5% CO2 for 24hr.

5.11.5.1.1 Immunohistochemistry

MG stable medium is firstly aspirated. Gently add ice cold methanol to each well and put well plate for 5 minutes into the -20°C freezer.

Have ice cold acetone in a glass bottle ready. Coverslips are dipped shortly into ice cold acetone and left to air dry on paper. Remaining coverslips which are not used for further analysis can be stored at -20C. Add 3% BSA blocking solution in 1x PBS for at least 45 minutes at room temperature. Aspirate off blocking solution. Prepare a 1/500 dilution of N68/6 Monoclonal mouse anti-Nav1.7 in 3% blocking solution. Add 250 ul to each coverslip and incubate for at least 1 h at room temperature. Wash three times with blocking solution. Add 1/1000 dilution of secondary antibodies in blocking solution (Invitrogen A11032 – 594 goat anti-mouse). Add 250 ul to each coverslip (except 1 one coverslip and incubation for 1 h at room temperature). Remember to include no primary antibody and no secondary antibody controls. Wash coverslips two times with blocking solution and two times with PBS. Finally add a 1/5000 dilution of DAPI/ PBS for nucleus staining. 250 ul of DAPI/PBS solution per well are added and incubated for 5 minutes at room temperature. Washing steps: three times with PBS, one time in ultra-pure sterile water. Mount cells with ProLong Gold antifade reagent and let coverslips mounted to glass slides dry on the slides overnight at 4 degrees. Coverslip edges are sealed with nail varnish before microscopy. Store slides at -20C.

5.11.5.2 Transfection of Nav1.7 and Nav1.6 stable cell line for patch clamp
Cell lines stably expressing Nav1.6 or Nav1.7 (see 5.11.1) are split into 2ml dishes and were grown to 90% confluence for transfection with (A) no DNA as a negative control to check for any contamination of either Lipofectamine 2000 (Invitrogen), Optimem (Invitrogen 11058-021),(B) pEGFP-N1 (see 5.9.3), to determine transfection efficiency and (C) EXPH1, expression vector pcDNA3 containing human full length Nav1.7 antisense transcript BC051759 (see section expression vector design 5.9.1A – 5.9.2.5) and (D) EXPH1 co transfection with pEGFP-N1 to detect transfected cells assuming that cells that take up the expression vector also take up pEGFP-N1. (E) Empty pcDNA3 vector as transcriptional control.

**Vector concentration:** (pEGFP-N1) =308ng/ul; (EXPH1) =413 ng/ul; (pcDNA3) = 2mg /ul. To obtain comparable results from each transfection for approached A – E an equal amount of DNA was used for transfection of the stably expressing Nav1.6 and Nav1.7 cell lines. Highest transfection efficacy was experimentally found at a DNA: Lipo2000 ratio of 1:2.5.

**Table 2 Overview of transfection approaches (patch clamp)**

<table>
<thead>
<tr>
<th>A. Reagent</th>
<th>No DNA</th>
<th>EGFP-N1</th>
<th>EXPH1</th>
<th>EGFP-N1+ EXPH1</th>
<th>pcDNA3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipo2000(ul)</td>
<td>3.125</td>
<td>0.625</td>
<td>2.5</td>
<td>3.125</td>
<td>2.5</td>
</tr>
<tr>
<td>Optimem (ul)</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. DNA used</th>
<th>concentration in ul</th>
<th>concentration in mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>No DNA</td>
<td>308ng/ul</td>
<td>413ng/ul</td>
</tr>
<tr>
<td>No DNA</td>
<td>0.81</td>
<td>2.42</td>
</tr>
<tr>
<td>No DNA</td>
<td>250</td>
<td>1000</td>
</tr>
</tbody>
</table>

Add Table 2 Overview of transfection approaches: gives a schematic overview of each performed transfection approach with reagents, concentrations, volumes and ratios used for each transfection approach. EXPH1 (see expression vector 5.9.2), pcDNA3 vector that has full length antisense transcript integrated. EGFP-N1, green fluorescence protein (see 5.9.3) to evaluate transfection efficiency.

Following transfection, cells are split to <50% confluence so that single cells can be analysed by patch clamping two days after transfection.
6. Results SCN9A and its corresponding antisense transcript

6.1. Bioinformatics

By browsing the human and mouse genomes for SCN9A, several ESTs are found on the GENOME UCSC browser (http://genome.ucsc.edu/) which are partially complementary to the SCN9A gene. SCN9A encodes for a voltage gated sodium channel which is predominantly found in DRG and sympathetic ganglion neurons.

In search for the human antisense gene, several expressed sequence tags (ESTs) (BC051759, BC029452, BM905527, BE566126, BG215777, AA383040) were found which suggested a cDNA/mRNA comprised of at least 12 exons, four of which are complementary overlapping the SCN9A sense exons encoded on chromosome 2. The longest human EST is BC051759. For all ESTs, five of their exons are associated with Alu’s, SINEs, and LINEs. The final exon has a polyadenylation signal and the first exon is not associated with a CpG island. For the mouse antisense gene, we identified the following antisense ESTs AK039017 (hypothalamus cDNA), AK045660 (corpora quadrigemina cDNA), AK020721 (hypothalamus cDNA), AK138511 (spinal cord) and AK138532 (spinal cord). Two of these ESTs are from the spinal cord where SCN9A is known to be expressed and suggests a cDNA comprised of 5/6 exons.

Bioinformatics comparison of the human and mouse antisense gene shows one of the exons is highly conserved between human and mouse and this maps to the final exon of the sense SCN9A gene.

To prove that the antisense gene exists and is not only an artefact, we screened for its expression in DRG neurons with mouse and human antisense specific primers. Mouse SCN9A antisense primers (See 5.10) M1.7 AS 1 FWD, M1.7 AS 1 REV expected size 625bp, M1.7 AS 3 FWD 5‘-, M1.7 AS 3 REV expected size 626bp. Human SCN9A antisense Primer H1.7 AS FWD 5’-GGAATTCAGGCAAAGTTGGA-‘3, H1.7 AS REV 5’-CAACCAACATTCAGCCATTG-‘3 with expected size of 991bp. DRG RNA was freshly prepared from black 6 mice and human DRG total RNA was purchased from Clontech. These DRG RNA samples were reverse-transcribed into cDNA and used as PCR templates.

Strong and clear bands for the human and mouse Nav1.7 antisense transcript appear on the agarosis gel suggesting that the SCN9A corresponding antisense transcript is not an artefact but a real transcript that is expressed in dorsal root ganglia. To further verify that the bands
for human and mouse Nav1.7 antisense transcript were as expected, the bands were cut out, gel purified and DNA sequenced.

**Fig 6.** (A) Clear and strong bands for M1 and M3 and (B) H1 and H3 suggest there is an antisense transcript expressed in mouse and human DRG neurons.

The primers which are used for sequencing are identical to the ones used for Phusion PCR reaction Mouse Nav1.7 AS 1 and 3, and Human Nav1.7 AS 1 and 3.

NCBI Blast ([http://blast.ncbi.nlm.nih.gov/Blast.cgi](http://blast.ncbi.nlm.nih.gov/Blast.cgi)) of human and mouse sequencing data against the whole genome gave a 100 per cent sequence ID of the human sequence data H1 and H3 to the human BC051759 antisense transcript and the mouse sequencing data M1 and M3 to the mouse AK138532 antisense transcript (supplemental data 2).
6.2 Mouse tissue panel

To test whether the sense and antisense transcripts are co expressed in different tissues, an RT-PCR using a mouse total RNA panel was performed. 15 different tissue specific RNA samples from the Clontech kit and one sample of freshly isolated DRG RNA were reverse-transcribed into cDNA with Superscript II and used as PCR templates with HPRT1, SCN9A sense and antisense specific primers. HPRT1 is a house keeping gene that is involved in the purine salvage pathways and was used as a reference PCR (56). HPRT1 is constantly and almost equally expressed in all tissue samples tested, confirming that reverse transcription was consistent and successful across all tissues. Furthermore, sequencing results verified that our specific primers correctly amplified the SCN9A and AK138532 antisense gene in the given gels. The agarosis gels show that SCN9A is highly expressed in DRG, brain, eye, smooth muscle and spinal cord samples. These findings are identical with the prior Microarray expression pattern Data for Mouse (GNF Expression Atlas 2 Data from GNF1M Mouse Chip, GENOME USCS). Although SCN9A is mainly found in the peripheral DRG neurons, it is also weakly expressed in the CNS. The microarray data also evaluates which brain tissue particularly expresses SCN9A: Hypothalamus and weak expression in the substantia nigra and the frontal cortex. (MICROARRAY, GENOME USCS)

Interestingly, SCN9A antisense transcript is mainly found in the brain, spinal cord, DRG and eye samples, with highest expression in the brain and spinal cord. In contrast to the SCN9A sense gene, the antisense gene is not detectable during any developmental stage or in smooth muscle tissue. Several studies have reported an important role for Nav1.7 in cultured human smooth muscle cells such as coronary arterial, pulmonary arterial and bronchial smooth muscle cells but not freshly isolated rabbit (58) aortic smooth muscle cells and human pulmonary artery smooth muscles (59). However, in brain, DRG, eye and spinal cord tissue samples, both sense and antisense transcripts co-expression was detected. Although it is very tempting to make an assumption about the expression level of sense and antisense gene in the used tissue samples due to variation in band intensity the expression levels needs to be fully evaluated by quantitative RT-PCR and protein levels assessed by western blotting. Nevertheless, this semi-quantitative result highlights that the sense and antisense transcripts are expressed in a broadly similar tissue expression pattern.
Sense and antisense specific PCR showed a significantly different expression pattern during development stages D7, D11 and D15. While the SCN9A sense gene is expressed during D11 and D15, SCN9A antisense transcript is not amplified from the D7 to D15 samples. It has been reported that the SCN9A sense gene has different splicing variants, one of which is neonatal (57). Exon 5 is alternatively spliced in SCN9A and its neonatal splicing variant has significantly different electrophysiological properties. The exact purpose of a neonatal splicing variant is yet not fully known. However, the complete absence of antisense transcript during the developmental stage D7 to D15 gives rise to the idea that the antisense transcript might shift the splicing event in favour of one transcript rather than the other. The proposed mechanism is that expression of the antisense transcript stabilizes the adult transcript, or binding masks the splicing site of the primary mRNA and therefore represses the neonatal splicing variant in favour of the adult one. The SCN9A sense primers were not specifically designed to detect a certain splice variant and unfortunately the bands appearing on the gel for the early developmental stages were not sequenced. Therefore there is no evidence that the bands on the gel are the neonatal splice variant. A different explanation for the absence of SCN9A antisense transcript in D7, D11 and D15 could be that SCN9A antisense transcript is only found in adult mice and has nothing to do with neonatal splicing variant or the antisense transcript was simply not detectable on the gel due to its low expression level.
**fig X** Mouse tissue panel for (A) Housekeeping gene (B) SCN9A sense and (C) SCN9A antisense gene. HPRT 1, a housekeeping gene, is expressed in all tissues and in all developmental stages tested. There is a spatial and temporal difference in the Nav1.7 sense and antisense transcript expression pattern. In particular, the mouse Nav1.7 antisense transcript is strongly expressed in the Brain, Eye, DRG neurons and spinal cord but seems not to be expressed during the early developmental stages D-7,-11 and D-15. In comparison Nav1.7 is expressed even during early development and is also found in brain, eye and spinal cord but as to be expected mainly in DRG neuron.
6.3 Immuno-histochemistry

Transfection of Nav1.7 stable cell line with SCN9A antisense transcript

We decided to investigate the effect of overexpressing the human antisense gene in a HEK293 stable Nav1.7 cell line. The effect of overexpressing the antisense transcript in this cell line was tested by immunohistochemistry (to semi-quantitatively assess SCN9A protein levels) and by patch clamping (to study the effect on Nav1.7 sodium currents).

An expression vector containing the human antisense transcript (BC051759) was cloned and transfected into the HEK293 Nav1.7 stable cells, along with an empty GFP vector to mark positively transfected cells (see transfection protocol 5.11.5.1).

It is assumed that cells that take up pEGFP are also taking up EXPH1 (the antisense construct).

One day after transfection the cells were fixed with methanol and stained with an anti-Nav1.7 antibody. Figures A-C and D-F show two fields of vision in which the antisense transcript was co-expressed with a GFP expression vector. **Fig A and D** show cells positively transfected with the GFP construct (and which also are likely to express the antisense transcript). **Figs B and E** show Nav1.7 protein stained in red. **Fig C and F** show nuclei stained with DAPI. The results show that cells which express GFP and the antisense construct are still stained with the anti-Nav1.7 antibody. There is therefore no obvious effect of overexpressing the antisense transcript on Nav1.7 protein levels. However, it must be noted that this is a cell line which itself artificially overexpresses Nav1.7, and the effect on protein levels of overexpressing the antisense transcript should be tested in cells which endogenously express Nav1.7 (such as DRG neurons) and also by a more quantitative technique.
**Fig A- F Immunohistochemistry.** HEK293 cells stably expressing Nav1.7 are co-transfected with a pcDNA3 vector containing SCN9A antisense transcript and a GFP vector and monitored 24h after transfection.

**A and D:** Cells positively transfected with pEGFP (and most likely the antisense construct) are shown in green. **B and E:** N68/6 monoclonal mouse anti-Nav1.7 antibody (Millipore) is used to detect the expression of Nav1.7 (in red) **C and F:** DAPI staining. DAPI (4’, 6-diamidino-2-phenylindole) can pass the membrane and binds to AT rich DNA region.

### 6.4 Electrophysiology

To functionally test the overexpression of the human Nav1.7 antisense transcript on sodium currents, cells stably expressing either Nav1.7 or Nav1.6 were transfected with (1) EXPH1 and pEGFP-N1 or (2) empty pcDNA3 and pEGFP-N1. Two days after transfection the cells were patch clamped (John Linley, Post-Doc, Molecular Nociception Group, London)
The results show that overexpression of the Nav1.7 antisense transcript in a cell line that stably expresses Nav1.7 results in a statistically significant reduction in the peak sodium current. In Nav1.6 stably expressing cells, overexpression of the Nav1.7 antisense construct has no effect on the sodium current. This shows that the Nav1.7 antisense transcript is specifically targeting Nav1.7.

**Fig Overexpression of human Nav1.7 antisense inhibits Nav1.7 but not Nav1.6 currents.**

Whole cell voltage clamp recording from HEK cells stably expressing human Nav1.7 or human Nav1.6. Cells were transiently transfected with either pCDNA3 vector or Nav1.7 antisense and recorded from 48hrs later. Peak whole cell current (pA) was measured in response to a 10 Ms voltage step from the holding potential of -120 mV to 0 mV and normalised to cell size (pF). N = 17-20; * indicates p<0.05 when compared to control (un-paired t-test).
7. Discussion

Through analyses of genome browsers and using RT-PCR of dorsal root ganglia cDNA, we have identified and cloned a SCN9A natural antisense transcript (NAT) that exists in both the human and mouse genomes. The human NAT is comprised of at least 12 exons, 4 of which partially overlap SCN9A sense exons and is polyadenylated. The mouse NAT is comprised of at least 6 exons, one of which is conserved with the human NAT and overlaps the final sense SCN9A coding exon, and is also polyadenylated. The human and mouse NATs are arranged in a tail-to-tail configuration with the sense genes.

Expression analysis using RT-PCR of a commercially available mouse RNA tissue panel show that the Scn9a sense and antisense genes are expressed in broadly similar tissues (e.g. DRG, spinal cord, brain and eye). This is important because the NAT may regulate sense mRNA/protein levels in tissues in which it is co-expressed with the sense gene. It is known that antisense genes can regulate the level of sense transcript through activation of the RNAi pathway. Here, RNAi could subsequently lead to a down regulation of functional Nav1.7 channels and therefore induce a shift in neuronal excitability due to absence of functional Nav1.7 sodium channels. In RNA masking, antisense-sense transcript hybridization might mask important ribosomal binding sites leading to a reduction in translated protein. A third possible way of how the NAT might disrupt the function of the sense gene is through transcriptional collision. To further investigate this mechanism, the NAT promoter should be characterised and the temporal correlation between sense and antisense transcription should be assessed in a cell line that endogenously expresses Nav1.7. The human Nav1.7 stable cell line has the clear disadvantage that Nav1.7 is ectopically expressed in these HEK cells and differs strongly in its physiological expression that is found in DRG neurons.

By overexpressing the human NAT in a cell line that stably expresses Nav1.7, we have shown that the NAT negatively regulates the SCN9A sense mRNA leading to a significant reduction in the peak sodium current. This effect is specific to Nav1.7 as overexpressing the Nav1.7 NAT in a stable Nav1.6 cell line had no effect on peak sodium current. Whether the SCN9A
natural antisense transcript negatively regulates SCN9A by RNAi or RNA masking is not known. However, this result gives scope to further investigating the effect of overexpressing the NAT in a cell which endogenously expresses Nav1.7. Furthermore, what is particularly exciting is the possibility that downregulation of the NAT (and hence upregulation of SCN9A) might underlie different pain states. To investigate this, we plan to assess the mRNA level of the sense and antisense gene in inflammatory and neuropathic mouse pain models using quantitative RT-PCR. Furthermore, the Nav1.7 protein level will also be monitored by western blotting in these pain models. Another interesting experiment planned is to use RNA in situ hybridization to study the localization of the NATs within a primary DRG neuron so that the effect of the NAT on local protein synthesis can be explored.

As mentioned earlier (results, 6.1 Bioinformatics) the human and mouse antisense transcript share one highly conserved exon. It will therefore be interesting to see if transfection the of the human Nav1.7 cell line with mouse EXPM1 antisense transcript also has an effect on electrophysical properties of the human Nav1.7 voltage gated sodium channel. Overexpression of human antisense gene in a stable Nav1.7 cell line leads to a reduction of peak current. In case the conserved exon plays a central part in antisense mediated regulation in both human and mouse it is expected that we will observe the same reduction in sodium peak current as seen with the human antisense transcript. If so, his would point toward a conserved regulatory mechanism which could then be explored further.

Nav1.7 is essential in nociception and not involved in any other major cellular pathways other than pain and the olfactory pathway. Therefore the Nav1.7 voltage gated sodium channel is an attractive target for a new class of analgesic drugs. Assuming that the SCN9A natural antisense transcript regulates endogenous SCN9A, it could be possible to interfere and control this regulation and thereby control the level of functional Nav1.7 sodium channels in DRG neurons in the clinic. Similarly, it has been postulated that a natural antisense transcript to the Huntington’s disease gene may have clinical applications (Ref is Chung et al 2011). So by fine tuning the level of functional Nav1.7 via antisense transcript expression it could be possible to restore normal pain thresholds even in patients suffering from inherited forms of Nav1.7 dysregulation.
References


23. Catterall W.A. From ionic currents to molecular mechanisms: The structure and
sodium channel alpha (II)-deficient mice. Biophys J 78:2878 –2891.
channels and pain pathways. Journal of Neurobiology, 61: 55–71. doi:
10.1002/neu.20094
27. Loss of function mutation in sodium channel Nav1.7 causes anomia ,Weiss J, Pyrski
M, Jacobi E, Bufe B, Willnecker V, Schick B, Zizzari P, Gossage SJ, Greer CA, Leinders-
2011 Mar PMID:21441906
29. Dib-Hajj SD, Binshtok AM, Cummins TR, Jarvis MF, Samad T, Zimmermann K.
Voltage-gated sodium channels in pain states: role in pathophysiology and targets
PubMed PMID: 19150627.
30. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and
20367448
specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and
in mice lacking both Nav1.7 and Nav1.8. Mol. Pain 1:24
induces robust alldynia and ectopic discharges in Nav1.3 null mutant mice. Mol.
Pain 2:33
34. Fischer TZ, Waxman SG. Familial pain syndromes from mutations of the Nav1.7


Weblinks and Bioinformatic databases: Overview

- International Association for the Study of Pain: IASP Taxomy
  http://www.iasp-pain.org
- Fantom mouse consortium, full mouse antisense clone description
- RestrictionMapper http://www.restrictionmapper.org/
- Double Digest Finder http://www.neb.com/nebecomm/DoubleDigestCalculator.asp
- Genome UCSC http://genome.ucsc.edu
- For full information on pEGFP vector with MCS
SUPPLEMENTAL DATA 1 - SCN9A protein structure

Primary amino acid sequence (5N+11RS)

10  20  30  40  50  60
./wwwt MAMLPPGPQSFVHFTKQSLALIEQRIAERKSKEPKEEKDDDDEEAFKPSDLEAGQLP
70  80  90 100 110 120
./wwwt FIYGDIPFVGMVEPLEDLPYADDKKTIFIVNKGKTIFRFNATPANYMLSPFSLRRI
130 140 150 160 170 180
./wwwt KLVHSLFSMLMCTILTINCIFTMNNPDWTKNEYFTFGITYFESLKILARGFVGVE
190 200 210 220 230 240
./wwwt FTFLRDPKNWLDFFVVFAYLTEFVNLGNVSLALTFRVLALKTSISVPGKTLIVGALIQ
250 260 270 280 290 300
./wwwt SVKKLSDQMTLVFCLSFLALQGFMNLHKCFRNSLENSNETLESIMNTESEEDFR
310 320 330 340 350 360
./wwwt KYFYYLEGSKDALLCGFSTSDSQCPPEGYTCVKIGRNPDYGTSSFDFTFSWALAFRLMTQ
370 380 390 400 410 420
./wwwt D'WENLYQQTLRAAGKyTMIFVVFVFIVGFSFLNILNLAVVAAAYEEQANIEEAQKE
430 440 450 460 470 480
./wwwt LEFQOMMLRLKKKEQEEAJAAAAAEYTSIRRSRIMGLFSSSETKSSKSASRENNR
490 500 510 520 530 540
./wwwt KKKNQKSSLGKEEGDAEKLSSKESEDSSIRKSFHLGVEGHRRAHEKRLSTPNSQLSIR
550 560 570 580 590 600
./wwwt GSLFSARSSRTSLFSFKGRGGRDIESETEFADDEHSIFGDNESRGRSLPVRPHPQERRSS
610 620 630 640 650 660
./wwwt NISQASRSPMLPVNGKMSAVDCNGVSSLGVDSALMPNQLLPE//GTNTNIKRRSCS
670 680 690 700 710 720
./wwwt SYLLSDMLNDPNLRQAMSRSAILNTNVEELEESRQKCPWWRFHAKFLIWNSPYWI
730 740 750 760 770 780
./wwwt KFKKCIYFIVMDPFDLAITICIVNLFMAMEHHPMTEEFKNVIANLILVFSTGIFAAEM
790 800 810 820 830 840
./wwwt VLKLAMDPYEFQVGWNIFDSLIVTLSLVELFLADVLEGLSVLRSFRRVFLAKSWPT
850 860 870 880 890 900
./wwwt LNMLIKIIGNSVGALGLTLVLAIVFIFAVGMOLFGKSYKECVCKINDDCTLPHMN
910 920 930 940 950 960
./wwwt DFFHSLIVFRVLCGEWIEWMDCMEVAGQANCLIVVMVMVGNLVVNLFFALLSSF
970 980 990 1000 1010 1020
./wwwt SSDNLTAIECDPDANHLQIAVTRIRKGINYQTLRFILKAFSKPRKSRIRQAEFL
1030 1040 1050 1060 1070 1080
A re-entrant loop between helices S5 and S6 is embedded into the transmembrane region of the channel to form the narrow, ion-selective filter at the extracellular end of the pore.

In ion trans I: 356-365
In ion trans II: 911-920
In ion trans III: 1390-1399
Transmembrane regions (Klugbauer)
Sodium Ion transport associated domain (SMART)
969-1191

Coiled coil region
402-449

IQ
1877-1899

Mutations
pedigree 44324 S459X
pedigree 22310 W897X
pedigree 21706 I767X

SNPs
rs12478318 G/T M➔L
rs4369876 A/C V➔L
rs6746030 A/G R➔W
rs3750904 C/T D➔G

Splice variants
Alternative coding exon 5:
YLTEFVNLGNVSAIYTRFVLRAKVTISVIP
YVTEFVDLGNVSAIYTRFVLRAKVTISVIP
For SCN8A it is said that this sequence encodes parts of transmembrane segments S3 and S4 within domain I \(^2,3\).

Extension of coding exon 11 at //:
VIIDKATSDDS

For SCN8A it is said that this encodes a portion of the cytoplasmic loop between domains I and II \(^4\).

**IFM motif**
In italics is the IFM motif. The sequence contains the IFM motif and the charged residues in the domain III-IV linker identified to be critical for the fast inactivation kinetics of the rat brain II channel \(^5\).

**Tetrodotoxin amino acid**
Highlighted in black is Y362 which can be mutated to Serine to make the channel tetrodotoxin-resistant \(^6\).


**Supplemental data 2 – Full length antisense, cDNA sequence Mouse**

**Sequence: AK 138532**

1 gagcaagagt aagaagtatt ggcaagccag gcacagcggg caggctgaga tcttgcatgg
61 aaatcatgaa ccaggtcttg cttttcgttt ttgaaacgtt ttgggaaggag agttatgaat
121 agcccaagaaa tagttctcct ttttgggta ggaagaatga ccagaagcag gaaagctaaa
181 tctctggcga atgtcgagggg acctctcttg ggtggtgcag taaaccccgag gggacgactt
241 ctctcgtgct caactcctgta acacatcaacat ctggagtgaa ggaaggggct ggtgaagcct
301 tgtaaaatat gcaaggggtg ctgtgcagag ctggtgagag ctttggtctg cctttaactc attgtggcga
361 agttggcagat cccaaagatg cgtgtagatga acatgacgag gaaagcagg aggcctgatgt
421 tgaacacgcgc aggaagggac atacatcagaa caagagcag cgtgcgggatc cccctggcgc
481 ctggcagcag cgtgtgagtt tgtcaaatcc tggccagggg aatgactcgg aacaggatgc
541 ctctcctcct gtcctgattc ctgctgagag ctttggtctg cctttaactc attgtggcga
601 cctctgctgt caactcctga accatcacat ctggagtgaa ggaaggggct ggtgaagcct
661 tgtaaaatat gcaaggggtg ctgtgcagag ctggtgagag ctttggtctg cctttaactc attgtggcga
721 gagatagggct ggagagtctg gaaacctgtg cggcagcata gggacacaag cggacaaacat caatgtaatcg
781 cgccacccata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcaagtct gggtgcgctac tgcctgataa tgagcttcg
841 cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
901 atggatgttg ggaagaccaac agactttcctt cagctctggg ccccaccttg agatccatag
961 gtttaacctt ttcagtttg tcttgtgtttc gttttctgta cggccagacct ccddagccttt
1021 ggtatactt gttcagggta aagagccca ggaatatcac cagacacag aatagctgt
1081 aggttgtggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
1201 cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
1261 cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
1321 cattacatata cagagaggtc gcacagcggg cgggtcagtt cggtgcctac tgaggcttac ccggcactatt
Human full length antisense, cDNA sequence
Sequence = BC051759

gtttagtcc tctgaatatt tttttttttt tcagaacctg aaaaaagatga atgaaatatta
  61 gttgttcccc ccctccgagag acacccagca cccacaacct cagactctga tgcctattgtg
 121 taatttatga agaataacca taactaaagat gaggtctgcg tattggtcct actgtagctt
 181 tgaaccttct gcctcaatgc atctctctgc atcagcatgc ggtgcatcact ggtatgaaag
 241 cagctgacac acatgcctagc acatggacta cagacttcag cgacagatcg tgcctgaca
 301 actgagactg agtgatgttc cctgctctag tttggaatct tttgcatgaa atagggactc
 361 tagccacacc cgcacccaaag aagtggcgcgt gagctctggtgc aatcctggca agacggatca
 421 caggaacctc gcacaaggtg gacattcctaa agaatggcggta gatgaacactg accacggaga
 481 gcaggaggcc gatgttaacac aacgcagggaa gggacatcata caaagcaagag agcagcagtgcc
 541 gacatccccct tgcctctctcg aacactgagtc gcaggcaact gcacagatcc aatgctggtgca
 601 ctcggaacag ggtaacagag aatcctgtag atggtccagt gcttcgaact gcagacttcgat
 661 ctacgccagcc tgtggctcttg agctcagcatg ccggtgcctgg aatcctggca agacggatca
 721 tgtggctcttg agctcagcatg ccggtgcctgg aatcctggca agacggatca
 781 cctttgctgc cgtgcacctg gctctcatttg atatctctttg atctctcttg ggtgctcttg catctctca
 841 ctctctgact gaaaaagttc atatgtaaatgc acatggccac ccagatcagc gccacagcagc
 901 aagtcgtttagg gatggctgatc ctgctctttt ggtgctcttg catctctca
 961 tgtggctcttg agctcagcatg ccggtgcctgg aatcctggca agacggatca
1021 aacactaagct gtaacctgact gaaaaagttc atatgtaaatgc acatggccac ccagatcagc gccacagcagc
1081 accacaaggg agagcatcttt ccctggcgag cccactgcag cccggtgacc ccaagtgacgata
1141 ataatttcctg cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1201 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1261 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1321 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1381 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1441 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1501 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1561 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1621 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1681 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1741 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1801 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1861 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1921 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
1981 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
2041 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
2101 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
2161 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
2221 ctgctctctct cttttctctct cttttctctct cttttctctct cttttctctct cttttctctct
2281 aaaaaaatttt cttccataatt tgg
Appendix – Diplomarbeit Jennifer König

AP1.1 1 kb DNA Ladder, Invitrogen
   http://products.invitrogen.com/ivgn/product/10787018
AP1.2 1 100kp DNA Ladder, Invitrogen
   http://products.invitrogen.com/ivgn/product/15628019
AP1.31 OneShot© Top10 chemically competent cells (Invitrogen C4040-10)
   http://products.invitrogen.com/ivgn/product/C404010
AP1.4 XL10-Gold ultracompetent Cells (Stratagene C- 200314).
   http://www.freewebs.com/labjuan2/XL10%20competent%20cells%20STRATAGENE.pdf
AP1.5 Miniprep (Qiagen Spin Miniprep kit)- Handbook
AP1.6 Maxiprep protocol see appendix Qiagen High speed Maxiprep kit
AP1.7 Gel purification, Qiagen Gel purification kit
AP1.8 PCR Purification
AP1.9 SuperScript RT (Invitrogen)
AP1.10 Phusion high fidelity PCR kit, Finnzymes F-553S/L
   http://www.finnzymes.com/pcr/phusion_high_fidelity_pcr_kit.html
AP1.11 Mouse total RNA master Panel (Clontech 636644)
AP1.12 Fantom CDNA clone
AP1.13 pcDNA3 with multiple cloning sites, Invitrogen
   http://products.invitrogen.com/ivgn/product/V79020
AP1.14 SAP, Alkaline Phosphatases, Roche
AP1.15 pEGFP-N1
AP1.16 DreamTaq Green DNA polymerase kit, Fermentas
CV - Jennifer König

Address: 65 Camden Road, Camden Town, London NW1 9EU
Phone: 07867933453
Email: jennifer.koenig@gmx.at, j.koenig@wibr.ucl.co.uk
Date of birth: 07.07.1986
Nationality: Austrian

RESEARCH EXPERIENCE

Nov 2010 – July 2011
Master Thesis, University College London
Department of Experimental Medicine, Molecular Nociception Group

Project title: Post-transcriptional regulation of SCN9A: an antisense transcript and RNA editing study
Description: The aim of this project is to ascertain whether the SCN9A mRNA undergoes RNA editing and hence alters the encoded protein sequence of Nav1.7
Techniques: Detection and amplification of SCN9 antisense mRNA
Supervisor: Prof. John N. Wood, PhD, FRS; James Cox, PhD;

July-August 2009
Internship, Centre of Brain Research
Department of Neuronal Cell Biology

Project title: Monitoring/ Detection of dendritically localized mRNA in hippocampal neurons
Description: The aim of the project was to investigate changes in P Body/RNP localisation and distribution due to chemical induced changes in neuronal activity. In addition to the localisation, the overall distribution of P- Bodies within a
neuron was detected. Therefore the RNP and P-body number within dendrites was determined as well as their spatial distribution.

**Techniques**  
By generating antisense probes complimentary to mRNAs (ARC, LimK) suspected to be crucial in dendritic development and P-Body marker. I performed several in situ hybridisations to compare RNA /P body distribution under various neuronal conditions (basal state, silenced and Glutamate) Real time imagining to determine mRNA / P body dynamics in hippocampal neurons.

**Supervisor**  
Prof Michael Kiebler, PhD; Georgia Vendra, PhD

---

**April– May 2009**

**Internship, Center of Brain Research**  
*Department of Neuroimmunology*

**Project title**  
The role of CKLF1 in the EAE Mouse model of Multiple Sclerosis

**Description**  
Certain chemokine’s preferentially enhance the migration of Th2 cells into the CNS. Chemokine like factor – 1 is a functional ligand of the CCR4 receptor and expressed on the surface of macrophages, dendritic cells and on the surface of Th2 cells. If Th2 cells are somehow recruited by chemokine like factor 1 they could function as potential key players in the shutdown of EAE by stimulating an immune protective pathway.

**Techniques**  
Purification and in vitro translation of CKLF1 which used to immunization of EAE mouse.

**Supervisor**  
Monika Bradl, PhD; Prof J. Lassmann, PhD

---

**Nov – Jan 2009**

**Neuroscience Program - Lab Rotation training**

*Center of Brain Research, Medical University of Vienna*  
*All Departments*

**Description**  
Practical training to acquire commonly used techniques in Neuroscience
Techniques  Elisa, Fura Imaging, immunocytochemistry, in situ hybridisation
measurement of electrophysical properties of neurons, microscopy and
sample preparation Receptor binding studies, Mass- spectroscope,
SuperFusion

2005-2008

Lab Courses during the 1st Diploma – Vienna Biocenter

Lab courses

Molecular biology and Genetics I, IIA+ IIB, III, Cell biology
Biochemistry, Organic chemistry, Inorganic chemistry, Microbiology I, II

Techniques  Acquisition of basic knowledge and skills in molecular biology for example:
PCR, Western --, Northern blot, cloning, protein purification, DNA and RNA extraction,
Bradford, Mass-spectrometry

CAREER AIM

Since my undergrad I’ve been really passionate about Neuroscience and Genetics, in
particular RNA Biology. Recently I came to realise that I would love to further knowledge in
Bioinformatics and DNA sequencing.

EDUCATION

Master Thesis  University College London  2010-2011
Molecular Nociception Group

Masters  University of Vienna  2008-2010
Lectures and lab courses in Molecular Neuroscience
Specialization: Neuroscience, Cell biology and
Molecular medicine

Université Aix- Marseille III  2009-2010
European exchange student. Following a course in cognitive and integrative Neuroscience

**Undergrad**

**University of Vienna**

1st Diploma in Molecular biology

*Key aspect:* Cell biology, Molecular biology, Neuroscience, ChemistryBiology, Grade: B;

**High school**

**Bundesoberstufenrealgymnasium (BORG)**

Grieskrichen, OÖ

A- Level with honour

**INTERESTS**

- Languages: fluent in German and English, French good but not fluent
- Travelling and Anthropology
- Art expositions
- Reading
- Salsa

**WORK EXPERIENCE**

Spring 2008  Sale advisor at H&M